Journal ArticleNPJ Precis Oncol · January 29, 2025
Black men suffer disproportionately from prostate cancer (PCa) compared to men of other races and ethnicities. Comparing the molecular landscape of PCa among Black and White patients has the potential to identify targets for development of new precision me ...
Full textLink to itemCite
Journal ArticleAnesth Analg · January 1, 2025
BACKGROUND: Obstructive sleep apnea is associated with increased dementia risk, yet its role in postoperative neurocognitive disorders is unclear. Here, we studied whether the severity of untreated obstructive sleep apnea is associated with the severity of ...
Full textLink to itemCite
Journal ArticleProstate cancer and prostatic diseases · June 2024
BackgroundNearly one-third of patients with prostate cancer (PCa) experience biochemical recurrence (BCR) after primary definitive treatment. BCR increases the risk of distant metastasis and mortality in patients with prognostically unfavorable fe ...
Full textCite
Journal ArticleProstate Cancer Prostatic Dis · June 2024
BACKGROUND: Biochemical recurrence (BCR) following primary interventional treatment occurs in approximately one-third of patients with prostate cancer (PCa). Next-generation imaging (NGI) can identify local and metastatic recurrence with greater sensitivit ...
Full textLink to itemCite
ConferenceAnesthesiology · May 1, 2024
BACKGROUND: Anesthesia and/or surgery accelerate Alzheimer's disease pathology and cause memory deficits in animal models, yet there is a lack of prospective data comparing cerebrospinal fluid (CSF) Alzheimer's disease-related biomarker and cognitive traje ...
Full textLink to itemCite
Journal ArticleProstate Cancer Prostatic Dis · September 2023
BACKGROUND: Urinary microbiota is implicated in many diseases of the urinary tract. The aim of this study was to perform a systematic review of the role of urinary microbiota in prostatic diseases. METHODS: A PubMed/Medline search was undergone from incept ...
Full textLink to itemCite
Journal ArticleWorld J Mens Health · July 2023
PURPOSE: Prostate cancer (PCa) screening can lead to potential over-diagnosis/over-treatment of indolent cancers. There is a need to optimize practices to better risk-stratify patients. We examined initial longitudinal outcomes of mid-life men with an elev ...
Full textLink to itemCite
Journal ArticleUrology · June 2023
OBJECTIVE: To describe the prevalence of PSA screening amongst transgender women. A transgender individual is someone whose gender identity differs from their birth sex or the societal norms of that assigned sex. There are no formal guidelines regarding PS ...
Full textLink to itemCite
Journal ArticleCan J Urol · June 2023
INTRODUCTION: The clinical utility of concurrent Prostate Health Index (PHI) and ExosomeDx Prostate Intelliscore (EPI) testing is unclear. We sought to examine the performance of combined PHI and EPI testing on men undergoing elevated PSA work up. MATERIAL ...
Link to itemCite
ConferenceUrology · May 2023
OBJECTIVE: To assess how the validated Prostate Health Index (PHI) risk stratifications perform with African American (AA) men and establish a threshold PHI value to potentially rule out the need for prostate biopsy. MATERIALS AND METHODS: AA men meeting F ...
Full textLink to itemCite
Journal ArticleUrol Clin North Am · November 2022
Despite newer therapies for castrate-resistant prostate cancer (CRPC), many patients do not experience a treatment response, and most eventually experience secondary resistance. Various androgen-receptor-related and alternative mechanisms of resistance in ...
Full textLink to itemCite
Journal ArticleCan J Urol · August 2022
Prostate-specific antigen (PSA) screening remains the mainstay for early detection of prostate cancer. Although PSA is a nonspecific prostate cancer biomarker, its specificity for high grade prostate cancer can be enhanced by pre-biopsy liquid biomarkers i ...
Link to itemCite
Journal ArticleEur Urol Focus · May 2022
Biomarkers are now ubiquitous in prostate cancer care. In addition to longstanding use of prostate-specific antigen, we now have secondary serum-, urine-, and tissue-based markers that help in optimizing patient care and patient compliance with therapeutic ...
Full textLink to itemCite
Journal ArticleOncology (Williston Park) · March 8, 2022
Prostate-specific antigen (PSA) values above 100 ng/mL often suggest metastatic prostate cancer. We present the case of a patient with a PSA of 110 ng/mL, 4 negative prostate biopsies, and 4 negative prostate MRIs. After his fifth MRI revealed a PI-RADS 5 ...
Full textOpen AccessLink to itemCite
Journal ArticleScientific reports · March 2022
TP53 is one of the most frequently altered genes in prostate cancer. The precise assessment of its focal alterations in primary tumors by immunohistochemistry (IHC) has significantly enhanced its prognosis. p53 protein expression and lymphovascular invasio ...
Full textCite
Journal ArticleAnn Clin Transl Neurol · February 2022
OBJECTIVE: Numerous investigators have theorized that postoperative changes in Alzheimer's disease neuropathology may underlie postoperative neurocognitive disorders. Thus, we determined the relationship between postoperative changes in cognition and cereb ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Geriatr Psychiatry Neurol · January 2022
OBJECTIVE: To determine the relationship between affective measures and cognition before and after non-cardiac surgery in older adults. METHODS: Observational prospective cohort study in 103 surgical patients age ≥ 60 years old. All participants underwent ...
Full textLink to itemCite
Journal ArticleBr J Anaesth · December 2021
BACKGROUND: Cognitive dysfunction after surgery is a major issue in older adults. Here, we determined the effect of APOE4 on perioperative neurocognitive function in older patients. METHODS: We enrolled 140 English-speaking patients ≥60 yr old scheduled fo ...
Full textOpen AccessLink to itemCite
Journal ArticleCan J Urol · August 2021
Prostatitis is a common cause of prostate-specific antigen (PSA) elevation but can masquerade underlying prostate cancer. We present a case of a man with undiagnosed prostate cancer whose initial PSA elevation of > 999.0 ng/mL was initially ascribed entire ...
Link to itemCite
Journal ArticleSci Rep · February 4, 2021
Arachidonic acid (AA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA) derived lipids play key roles in initiating and resolving inflammation. Neuro-inflammation is thought to play a causal role in perioperative neurocognitive disorders, yet th ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Urol · February 2021
PURPOSE: Nonadherence to dosing schedules for androgen deprivation therapy increases the risk of testosterone escape for patients with prostate cancer. Two approved formulations of leuprolide acetate, the most commonly prescribed androgen deprivation thera ...
Full textLink to itemCite
Journal ArticleJ Alzheimers Dis · 2021
BACKGROUND: Postoperative cognitive dysfunction (POCD), a syndrome of cognitive deficits occurring 1-12 months after surgery primarily in older patients, is associated with poor postoperative outcomes. POCD is hypothesized to result from neuroinflammation; ...
Full textOpen AccessLink to itemCite
Journal ArticleOncology (Williston Park) · September 15, 2020
Judd W. Moul, MD, discusses the effects that COVID-19 may have on the outcomes for patients with cancer in the United States and throughout the world. ...
Full textLink to itemCite
Journal ArticleUrol Pract · September 2020
INTRODUCTION: We analyzed trends and explored implications of no-show rates in adult urology from provider related characteristics at an academic program. METHODS: No-show rates were determined from electronic health records of appointments in adult urolog ...
Full textLink to itemCite
Journal ArticleJ Neurol · July 2020
OBJECTIVE: Lumbar punctures (LPs) are important for obtaining CSF in neurology studies but are associated with adverse events and feared by many patients. We determined adverse event rates and pain scores in patients prospectively enrolled in two cohort st ...
Full textLink to itemCite
Journal ArticleClin Cancer Res · June 15, 2020
PURPOSE: Both weight loss and low-carbohydrate diets (LCD) without weight loss prolong survival in prostate cancer models. Few human trials have tested weight loss or LCD on prostate cancer. EXPERIMENTAL DESIGN: We conducted a multi-site randomized 6-month ...
Full textLink to itemCite
Journal ArticleJ Geriatr Oncol · June 2020
BACKGROUND: Given the potential complications of prostate biopsies, it is sometimes reasonable in selected patients to make a non-tissue diagnosis of prostate cancer. Little is known about prevalence and factors associated with non-tissue prostate cancer d ...
Full textLink to itemCite
Journal ArticleOncology (Williston Park) · May 13, 2020
The coronavirus disease 2019 pandemic has rapidly placed tremendous stress on health systems around the world. In response, multiple health systems have postponed elective surgeries in order to conserve hospital beds and personal protective equipment, mini ...
Open AccessLink to itemCite
Journal ArticleBJUI Compass · May 2020
OBJECTIVES: To assess the impact of patient age and weight on the pharmacokinetics (PK), testosterone (T) suppression and safety from four fixed dosing regimens (7.5, 22.5, 30, or 45Â mg for 1-, 3-, 4-, or 6-months, respectively) of subcutaneous in situ gel ...
Full textLink to itemCite
Journal ArticleThe Journal of urology · April 2020
PurposeWe evaluated the timeliness of androgen deprivation therapy dosing, the impact of dosing nonadherence on testosterone, and the frequency of testosterone and prostate specific antigen testing in patients with prostate cancer.Materials an ...
Full textCite
Journal ArticleJ Alzheimers Dis · 2020
BACKGROUND: Perioperative neurocognitive disorders (PND) are common complications in older adults associated with increased 1-year mortality and long-term cognitive decline. One risk factor for worsened long-term postoperative cognitive trajectory is the A ...
Full textOpen AccessLink to itemCite
Journal ArticleEur Urol Focus · November 2019
CONTEXT: Vesicourethral anastomosis (VUA) is a crucial step during radical prostatectomy (RP). Generally, either a continuous (CS) or an interrupted suture (IS) is used. However, there is no clear evidence if one technique is superior to the other. OBJECTI ...
Full textLink to itemCite
Journal ArticleAnesth Analg · November 2019
Animal models suggest postoperative cognitive dysfunction may be caused by brain monocyte influx. To study this in humans, we developed a flow cytometry panel to profile cerebrospinal fluid (CSF) samples collected before and after major noncardiac surgery ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Urol · September 2019
PURPOSE: Current trends in renal transplantation, such as improved allograft/recipient survival and expanded organ transplantation eligibility criteria in older recipients, are concomitant with increasingly detected low risk prostate cancer in candidates f ...
Full textLink to itemCite
Journal ArticleCan J Urol · June 2019
Urologists have been using oral nonsteroidal antiandrogens (AA) for 30 years as a component of combined androgen blockade. In February 2018, a new third generation AA, apalutamide, became available for the first time for non-metastatic (M0) castrate resist ...
Open AccessLink to itemCite
Journal ArticleJ Am Geriatr Soc · April 2019
BACKGROUND/OBJECTIVES: Every year, up to 40% of the more than 16 million older Americans who undergo anesthesia/surgery develop postoperative cognitive dysfunction (POCD) or delirium. Each of these distinct syndromes is associated with decreased quality of ...
Full textOpen AccessLink to itemCite
Journal ArticleThe Journal of urology · November 2018
PurposeAntiandrogens inhibit the androgen receptor and have an important role in the treatment of prostate cancer. This review provides a historical perspective on the development and clinical benefit of antiandrogens in the treatment of prostate ...
Full textCite
Journal ArticleClin Genitourin Cancer · April 2018
INTRODUCTION: This multicenter phase 2 study assessed the combination of estramustine and weekly paclitaxel with metastatic castration-resistant prostate cancer (CRPC). PATIENTS AND METHODS: We enrolled 77 patients who had received no prior chemotherapy fo ...
Full textLink to itemCite
Journal ArticleJ Urol · March 2018
PURPOSE: Nonrepresentative biopsy sampling of prostate cancers with a biopsy Gleason score of 8 can adversely influence decisions regarding androgen deprivation in men receiving primary radiation therapy. The frequency of and factors associated with downgr ...
Full textLink to itemCite
ConferenceJournal of Clinical Oncology · February 20, 2018
382 Background: Nearly one third of men treated with curative intent for localized prostate cancer (PC) will develop a rising PSA. The rate of PSA rise (PSA doubling time aka PSASDT) is a predictor metastases and PC death. In lab ...
Full textCite
Journal ArticleJ Clin Oncol · February 1, 2018
Purpose Guidelines are limited for genetic testing for prostate cancer (PCA). The goal of this conference was to develop an expert consensus-driven working framework for comprehensive genetic evaluation of inherited PCA in the multigene testing era address ...
Full textLink to itemCite
Journal ArticleTher Adv Urol · February 2018
BACKGROUND: The aim of this study was to compare the pharmacokinetics (PK) and pharmacodynamics (PD) of two distinct formulations of leuprolide acetate (LA); subcutaneous (SC) injection and intramuscular (IM) injection. METHODS: A total of 32 healthy men w ...
Full textLink to itemCite
Journal ArticleScand J Urol · 2018
BACKGROUND: Gonadotropin releasing hormone (GnRH) antagonists suppress follicle-stimulating hormone (FSH) to lower levels than GnRH agonists. This may partially explain the differences between these agents on prostate cancer outcomes. In this post-hoc anal ...
Full textLink to itemCite
Journal ArticleAm J Mens Health · November 2017
It is controversial whether African American men(AAM) with low-risk prostate cancer (PC) should be placed on active surveillance (AS). Recent literature indicates AAM diagnosed with low-risk disease have increased pathologic upgrading and disease progressi ...
Full textLink to itemCite
Journal ArticleCan J Urol · October 2017
INTRODUCTION: Contemporary clinical guidelines utilize the highest Gleason sum (HGS) in any one core on prostate biopsy to determine prostate cancer treatment. Here, we present a large discrepancy between prostate cancer risk stratified as high risk on bio ...
Link to itemCite
Journal ArticleProstate Cancer Prostatic Dis · September 2017
BACKGROUND: Active surveillance (AS) has excellent short to medium term outcomes in well-selected prostate cancer patients. Traditional biopsy-based selection criteria have been criticized for inaccurate determination of cancer grade and extent. We evaluat ...
Full textLink to itemCite
Journal ArticleCurr Urol Rep · July 2017
PURPOSE OF REVIEW: Growing research supports the use of multiparametric magnetic resonance imaging (mpMRI) for the evaluation of localized prostate cancer (PCa). We highlight contemporary evidence supporting its use in active surveillance (AS). RECENT FIND ...
Full textLink to itemCite
ConferenceJournal of Clinical Oncology · May 20, 2017
e16566 Background: A CCP score has been developed and validated to provide prognostic information in prostate cancer. To date, our studies have exclusively used qRT-PCR to measure CCP gene expression, which is generally considere ...
Full textCite
Journal ArticleOncology (Williston Park) · April 15, 2017
Sexual and urinary morbidities resulting from treatment of pelvic malignancies are common. These treatment sequelae are significantly bothersome to patients and challenging to address. Awareness of these complications is critical in order to properly couns ...
Link to itemCite
ConferenceJournal of Clinical Oncology · February 20, 2017
e589 Background: Leuprolide acetate (LA) is the standard-of-care luteinizing hormone-releasing hormone (LHRH) agonist used to suppress serum testosterone (T) in the treatment of advanced prostate cancer. There are currently two L ...
Full textCite
Journal ArticleBJU Int · February 2017
OBJECTIVE: To determine whether luteinising hormone-releasing hormone (LHRH) agonist, ATRIGEL® polymer-delivered, subcutaneous, leuprolide acetate (ADSC-LA), formulations suppressed serum testosterone to concentrations of ≤20 ng/dL. PATIENTS AND METHODS: D ...
Full textLink to itemCite
Journal ArticleFront Syst Neurosci · 2017
Each year over 16 million older Americans undergo general anesthesia for surgery, and up to 40% develop postoperative delirium and/or cognitive dysfunction (POCD). Delirium and POCD are each associated with decreased quality of life, early retirement, incr ...
Full textOpen AccessLink to itemCite
Journal ArticleCurr Opin Urol · November 2016
PURPOSE OF REVIEW: Oligometastatic prostate cancer (PCA) has increasingly been detected in the era of modern imaging studies such as choline-specific and prostate-specific membrane antigen (PSMA)-positron emission tomography and X-ray computed tomography ( ...
Full textLink to itemCite
Journal ArticleWorld J Urol · August 2016
PURPOSE: To assess the prostate-specific antigen (PSA) threshold value that optimally predicts future risk of prostate cancer (overall and by race) for a dispersed US population. METHODS: This was a retrospective analysis of men in the Veterans Affairs (VA ...
Full textLink to itemCite
Journal ArticleInt J Cancer · June 1, 2016
Prostate cancer (PC) has the highest degree of genetic transmission of any form of malignancy. In some families, the hereditary pattern is so strong as to mimic an autosomal dominance trait. We reviewed the known predisposing genetic markers to assess poss ...
Full textLink to itemCite
ConferenceProstate Cancer Prostatic Dis · March 2016
BACKGROUND: In men with high Gleason PC and rapid PSA progression after surgery, failure rates remain unacceptably high despite salvage radiation. We explored a novel multimodality approach of docetaxel with anti-angiogenic therapy before salvage radiother ...
Full textLink to itemCite
Journal ArticleClin Geriatr Med · February 2016
The impact of localized prostate cancer in the elderly depends on disease aggressiveness and life expectancy. In men with localized prostate cancer, those with low-risk disease or a shorter life expectancy should be managed expectantly, whereas those with ...
Full textLink to itemCite
ConferenceJournal of Clinical Oncology · January 10, 2016
84 Background: Active surveillance (AS) is an increasingly popular treatment modality for men with localized prostate cancer. Recently, we developed a method to select men for AS based on a score that combines cell cycle progress ...
Full textCite
Journal ArticleExpert Rev Anticancer Ther · 2016
Multi-parametric MRI (mpMRI) is widely used in the detection and characterization of clinically- significant prostate cancer. MRI-TRUS (trans-rectal ultrasound) fusion biopsy is an in-office procedure that promises to empower urologists to successfully tar ...
Full textLink to itemCite
Chapter · January 1, 2016
Population screening for prostate cancer (PCa) is a very controversial and hot topic! In the first 20 years from adoption of the prostate-specific antigen (PSA) test, some organizations supported population-based screening as PSA testing came into widespre ...
Full textCite
Journal ArticleClin J Oncol Nurs · June 2015
BACKGROUND: Sipuleucel-T, an autologous cellular immunotherapy, is approved for the treatment of certain patients with metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T is the first personalized treatment for prostate cancer to be manuf ...
Full textLink to itemCite
Journal ArticleCurr Opin Urol · May 2015
PURPOSE OF REVIEW: In the absence of whole gland treatment for prostate cancer, both active surveillance and focal therapy share the common need of requiring a more thorough, detailed and precise analysis of the biological threats within the prostatic pare ...
Full textLink to itemCite
Journal ArticleBiotech Histochem · April 2015
In vitro bioassay has been used extensively to test the effects of culturing cancer cells in sera from humans participating in dietary interventions, i.e, studies of modified intake of nutrients for the purpose of reducing cancer risk or progression. It ha ...
Full textLink to itemCite
Journal ArticleOncology (Williston Park) · January 2015
Androgen deprivation therapy (ADT) is key to the treatment of men with advanced prostate cancer. ADT can consist of surgical (bilateral orchiectomy) or medical strategies (eg, luteinizing hormone-releasing hormone agonists or gonadotropin-releasing hormone ...
Link to itemCite
Journal ArticleAsian J Androl · 2015
Hormone naïve advanced prostate cancer is subdivided into two disease states: biochemical recurrence and traditional M1 (metastatic) prostate cancer and characterized by no prior hormonal therapy or androgen deprivation therapy (ADT). In biochemical recurr ...
Full textOpen AccessLink to itemCite
Journal ArticleExpert Opin Drug Metab Toxicol · 2015
INTRODUCTION: Luteinizing hormone-releasing hormone agonists such as leuprolide acetate (LA) are the most frequently utilized treatment of advanced prostate cancer as the regimen for achieving androgen deprivation therapy (ADT). The efficacy of LA is deter ...
Full textLink to itemCite
Journal ArticleOncology (Williston Park, N.Y.) · 2015
Androgen deprivation therapy (ADT) is key to the treatment of men with advanced prostate cancer. ADT can consist of surgical (bilateral orchiectomy) or medical strategies (eg, luteinizing hormone-releasing hormone agonists or gonadotropin-releasing hormone ...
Cite
Journal ArticleOncol Res Treat · 2015
Up to 12% of European men aged 55-69 years diagnosed with prostate cancer have high-risk disease and thus are at increased risk of mortality. There remains a lack of consensus on definitive treatment for prostate cancer, although both radiation therapy and ...
Full textLink to itemCite
Journal ArticleUrology · December 2014
OBJECTIVE: To assess whether NADiA ProsVue prostate-specific antigen slope, a prognostic biomarker for identifying men at a reduced risk of clinically recurrent prostate cancer after radical prostatectomy, is prognostic for prostate cancer--specific mortal ...
Full textLink to itemCite
Journal ArticleCurr Med Res Opin · May 2014
OBJECTIVE: To compare acute normovolemic hemodilution versus low central venous pressure strategy versus conventional fluid management in reducing intraoperative estimated blood loss, hematocrit drop and need for blood transfusion in patients undergoing ra ...
Full textLink to itemCite
Journal ArticleCan J Urol · April 2014
INTRODUCTION: Androgen deprivation therapy (ADT) is the lynchpin of treatment for advanced prostate cancer. Prescribing physicians and patients have a choice between orchiectomy, luteinizing hormone releasing hormone (LHRH) agonists, combined androgen depr ...
Link to itemCite
Journal ArticleJ Clin Oncol · March 1, 2014
PURPOSE: Prognostic models for overall survival (OS) for patients with metastatic castration-resistant prostate cancer (mCRPC) are dated and do not reflect significant advances in treatment options available for these patients. This work developed and vali ...
Full textLink to itemCite
Journal ArticleRev Urol · 2014
Prostate-specific antigen (PSA) screening is associated with a decline in prostate cancer-related mortality. However, screening has also led to overdiagnosis and overtreatment of clinically insignificant tumors. Recently, certain national guidelines (eg, U ...
Link to itemCite
Chapter · January 1, 2014
Prostate cancer is the second most common cancer in men worldwide [ 1 ]. In the USA alone, 239,000 men will be diagnosed with prostate cancer in 2013 and 30,000 will die of the disease. Overall, 1 in every 6 men in the USA will be diagnosed with prostate c ...
Full textCite
Book · January 1, 2014
Urology at a Glance is a concise, practical guide to diagnostic and therapeutic decision making. The book is divided into two parts. The first focuses on the pathway from symptom to diagnosis and covers the full range of symptoms commonly encountered by th ...
Full textCite
Journal ArticleJ Clin Oncol · May 10, 2013
PURPOSE As part of the ENTHUSE (Endothelin A Use) program, the efficacy and safety of zibotentan (ZD4054), an oral specific endothelin A receptor antagonist, has been investigated in combination with docetaxel in patients with metastatic castration-resista ...
Full textLink to itemCite
Journal ArticleJ Med Food · April 2013
Enterolactone and enterodiol, mammalian lignans derived from dietary sources such as flaxseed, sesame seeds, kale, broccoli, and apricots, may impede tumor proliferation by inhibiting activation of nuclear factor kappa B (NFκB) and vascular endothelial gro ...
Full textLink to itemCite
Journal ArticleProstate Cancer Prostatic Dis · March 2013
BACKGROUND: Active surveillance (AS) is increasingly utilized in low-risk prostate cancer (PC) patients. Although black race has traditionally been associated with adverse PC characteristics, its prognostic value for patients managed with AS is unclear. ME ...
Full textLink to itemCite
Journal ArticleMed Oncol · March 2013
To assess preoperative parameters that may be predictive of pathologic stage T2a (pT2a) and pathologic Gleason score (pGS) ≤ 6 disease in low-risk prostate cancer patients considering active surveillance. A cohort of 1,495 men with low-risk prostate cancer ...
Full textLink to itemCite
Journal ArticleAndrology · March 2013
Changes in sexual bother (SB) following radical prostatectomy (RP) negatively affect health-related quality of life (HRQoL) of prostate cancer survivors. However, post-operative SB tends to be neglected whereas sexual function (SF) is thoroughly assessed i ...
Full textLink to itemCite
ConferenceJournal of Clinical Oncology · February 20, 2013
139 Background: The post-radical prostatectomy (RP) CAPRA-S nomogram stratifies men into low, intermediate and high risk groups for biochemical recurrence (BCR) and proved accurate for predicting 3 and 5 year BCR rates in a large ...
Full textCite
Journal ArticleJ Clin Oncol · February 20, 2013
56 Background: Image-guided radiation therapy (IGRT) has been widely adopted for both definitive and post-operative prostate radiotherapy. In the postoperative setting, numerous studies of prostate bed motion have recommended tight planning margins (<10mm) ...
Full textLink to itemCite
Journal ArticleUrology · December 2012
OBJECTIVE: To validate the hypothesis that men displaying serum prostate-specific antigen (PSA) slopes ≤ 2.0 pg/mL/mo after prostatectomy, measured using a new immuno-polymerase chain reaction diagnostic test (NADiA ProsVue), have a reduced risk of clinica ...
Full textLink to itemCite
Journal ArticleProstate Cancer Prostatic Dis · December 2012
BACKGROUND: Incremental cost-effectiveness ratios (ICERs) of finasteride for prostate cancer prevention are consistent with estimates beyond $100 000 per quality-adjusted life-year (QALY). The majority of these analyses are based on chemoprevention startin ...
Full textLink to itemCite
Journal ArticleMed Oncol · December 2012
To find the predictors of Gleason score upgrading in a cohort of low-risk prostate cancer patients, data were analyzed comprising 1,632 consecutive men with low-risk prostate cancer who underwent radical prostatectomy between 1993 and 2009. Assessment focu ...
Full textLink to itemCite
Journal ArticleCancer · November 15, 2012
BACKGROUND: Endothelin-1 and the endothelin A (ET(A) ) receptor have been implicated in prostate cancer progression in bone. This study aimed to determine whether the specific ET(A) receptor antagonist, zibotentan, prolonged overall survival (OS) in patien ...
Full textLink to itemCite
Journal ArticleAm J Mens Health · September 2012
Research examining psychosocial functioning in African American prostate cancer survivors has been limited, in spite of documented higher mortality from prostate cancer and worse long-term physical and emotional outcomes from prostate cancer treatment repo ...
Full textLink to itemCite
Journal ArticleBJU Int · August 2012
OBJECTIVE: • Androgen stimulation of prostate cancer (PCa) cells has been extensively studied. The increasing trend of using serum testosterone as an absolute surrogate for castration state means that the diagnostic measurement of testosterone and the valu ...
Full textLink to itemCite
Journal ArticleJ Urol · July 2012
PURPOSE: Understanding the extent of disease in asymptomatic patients with castration resistant prostate cancer is important when making treatment decisions and designing clinical trials. The ENTHUSE M0 (ENdoTHelin A USE) trial (NCT00626548) was a large ph ...
Full textLink to itemCite
Journal ArticleJ Sex Med · June 2012
INTRODUCTION: Chronic oxidative stress is one of the major factors playing an important role in radiation-induced normal tissue injury. However, the role of oxidative stress in radiation-induced erectile dysfunction (ED) has not been fully investigated. Ai ...
Full textLink to itemCite
Journal ArticleEur Urol · April 2012
Featured Publication
CONTEXT: The optimal management strategy for men with newly diagnosed clinically localized prostate cancer remains a matter of debate. Numerous series have reported cancer control and quality-of-life (QoL) outcomes following treatment with radical prostate ...
Full textLink to itemCite
Journal ArticleJ Sex Med · April 2012
INTRODUCTION: Erectile dysfunction (ED) is related to several co-morbidities including obesity, metabolic syndrome, cigarette smoking, and low testosterone, all of which have been reported to be associated with adverse prostate cancer features. AIM: To exa ...
Full textLink to itemCite
Journal ArticleInt J Radiat Oncol Biol Phys · April 1, 2012
Featured Publication
PURPOSE: To determine whether an increasing number of high-risk factors is associated with higher prostate cancer-specific mortality (PCSM) among men treated with brachytherapy (BT)-based treatment, and whether supplemental therapy has an impact on this ri ...
Full textLink to itemCite
Journal ArticleJ Urol · March 2012
Featured Publication
PURPOSE: We previously found that patients undergoing robotic assisted laparoscopic radical prostatectomy vs radical retropubic prostatectomy had a higher likelihood of not being satisfied, independent of side effect profile. We hypothesized that different ...
Full textLink to itemCite
Journal ArticleEur Urol · March 2012
CONTEXT: Approximately 15-25% of men who undergo radical prostatectomy for localized prostate cancer (PCa) will experience recurrence of their cancer; men with poorly differentiated cancer, non-organ-confined disease, and positive surgical margins are at t ...
Full textLink to itemCite
Journal ArticleJ Clin Oncol · February 10, 2012
34 Background: Despite a substantial effort to study the clinical significance of perineural invasion in prostate biopsies (PNIb) its prognostic significance remains controversial. The limited data on perineural invasion in radical prostatectomy (RP) speci ...
Link to itemCite
Journal ArticleJ Clin Oncol · February 10, 2012
246 Background: Little is known about physicians' (MDs) and prostate cancer (PC) patients' (pts) levels of awareness or concern about bone health or how/when MDs discuss bone health with at-risk pts. An online survey was conducted to explore these issues a ...
Link to itemCite
Journal ArticleJ Clin Oncol · February 10, 2012
34 Background: Despite a substantial effort to study the clinical significance of perineural invasion in prostate biopsies (PNIb) its prognostic significance remains controversial. The limited data on perineural invasion in radical prostatectomy (RP) speci ...
Full textLink to itemCite
Journal ArticleJ Clin Oncol · February 10, 2012
246 Background: Little is known about physicians' (MDs) and prostate cancer (PC) patients' (pts) levels of awareness or concern about bone health or how/when MDs discuss bone health with at-risk pts. An online survey was conducted to explore these issues a ...
Full textLink to itemCite
Journal ArticleProstate · February 2012
Featured Publication
BACKGROUND: Most prostate cancer-related deaths occur in patients with castration-resistant prostate cancer (CRPC). Recent preclinical and clinical studies have identified intracellular signaling pathways and changes in the tumor and bone microenvironment ...
Full textLink to itemCite
Journal ArticleProstate · February 1, 2012
Featured Publication
BACKGROUND: Baseline prostate specific antigen (PSA) and PSA velocity used to stratify subsequent prostate cancer risk in young men may not directly applicable to all populations. We sought to compare the baseline PSA and PSA velocity among ethnic groups. ...
Full textLink to itemCite
Journal ArticleUrol Oncol · 2012
Featured Publication
OBJECTIVE: To evaluate the association between prostate weight and the diagnostic performance of routine biopsy schemes in detecting unilateral prostate cancer (PCa) that may be amenable to focal therapy. METHODS AND MATERIALS: Retrospective analysis of pa ...
Full textLink to itemCite
Journal ArticleCancer Invest · January 2012
Featured Publication
The development of new therapies for castration-resistant prostate cancer (CRPC) has increasingly focused on improving patient quality of life, mainly because of limited survival gains and continuing high morbidity burden from disease progression or the ad ...
Full textLink to itemCite
Journal ArticleEur Urol · January 2012
Featured Publication
CONTEXT: Prostate cancer screening is highly controversial, including the age to begin prostate-specific antigen (PSA) testing. Several studies have evaluated the usefulness of baseline PSA measurements at a young age. OBJECTIVE: Review the literature on b ...
Full textLink to itemCite
Journal ArticleJ Urol · January 2012
Featured Publication
PURPOSE: The multidisciplinary approach is becoming increasingly encouraged but little is known about the multidisciplinary experience compared to routine care. For patients with prostate cancer the goal is to provide evaluations by urologists, medical and ...
Full textLink to itemCite
Journal ArticleInt J Radiat Oncol Biol Phys · January 1, 2012
PURPOSE: To evaluate the primary Gleason grade (GG) in Gleason score (GS) 7 prostate cancers for risk of non-organ-confined disease with the goal of optimizing radiotherapy treatment option counseling. METHODS: One thousand three hundred thirty-three patie ...
Full textLink to itemCite
Journal ArticleUrol Int · 2012
OBJECTIVE: To assess preoperative parameters that may be predictive of pathologic stage T2a disease in low-risk prostate cancer patients. METHODS: Data from a cohort of 1,495 consecutive men with low-risk prostate cancer who underwent a radical prostatecto ...
Full textLink to itemCite
Journal ArticlePLoS One · 2012
Previous observational studies have reported associations between prostate cancer and alpha-linolenic acid (ALA). However, few investigations have been able to study this relationship prospectively and in well-controlled settings. Moreover, no studies have ...
Full textOpen AccessLink to itemCite
Journal ArticleProstate Cancer Prostatic Dis · December 2011
Featured Publication
The American Cancer Society's updated screening guidelines for prostate cancer (CaP) render digital rectal examination (DRE) optional. We investigated the impact of DRE on CaP detection among obese men. Data from 2794 men undergoing initial prostate biopsy ...
Full textLink to itemCite
Journal ArticleBJU Int · December 2011
Featured Publication
UNLABELLED: What's known on the subject? and What does the study add? Large population screening trials like the ERSPC, PCPT and PLCO have noted that men with seemingly low PSA (even as low as 0.5 ng/dL) still can have prostate cancer. Despite these findin ...
Full textLink to itemCite
Journal ArticleUrology · November 2011
The Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE) is an ongoing longitudinal observational study of current trends in prostate cancer staging and treatment across a spectrum of different treatment facilities in the United States. ...
Full textLink to itemCite
Journal ArticleUrology · November 2011
Featured Publication
For most of the past 25 years, 1 of the favored approaches to treating prostate cancer has been the suppression of circulating testosterone with luteinizing hormone-releasing hormone (LHRH) agonists. LHRH agonists produce a downregulation of LHRH receptors ...
Full textLink to itemCite
Journal ArticleUrology · November 2011
Intensive investigation during the past 2 decades has led to an improved knowledge of the biology of the androgen receptor and a better understanding of how to assess for disease progression and the apparent existence of castrate-resistant prostate cancer. ...
Full textLink to itemCite
Journal ArticleUrology · November 2011
Featured Publication
Until the 1980s, testosterone suppression for men with advanced prostate cancer was managed surgically, with bilateral orchiectomy, or medically, with diethylstilbestrol, a drug that was associated with a problematic side effect profile. Beginning in the m ...
Full textLink to itemCite
Journal ArticleUrology · November 2011
Since Huggins and Hodges first established testosterone as the principal androgenic hormone responsible for the growth of prostate cancer in 1941, lowering the circulating testosterone to surgical castration levels (<50 ng/dL) has been a fundamental strate ...
Full textLink to itemCite
Journal ArticleJ Sex Med · October 2011
INTRODUCTION: The association between early and late phase sexual health-related quality of life (HRQoL) following radical prostatectomy (RP) is unclear. Moreover, factors that predict either early or late sexual HRQoL decline have not been fully investiga ...
Full textLink to itemCite
Journal ArticleJ Urol · September 2011
PURPOSE: We investigated the efficacy and safety of degarelix treatment and the effects of switching from leuprolide to degarelix in an ongoing extension study with a median 27.5-month followup of a pivotal 1-year prostate cancer trial. MATERIALS AND METHO ...
Full textLink to itemCite
Journal ArticleCancer · September 1, 2011
Featured Publication
BACKGROUND: A survival benefit has been observed with salvage radiation therapy (RT) for prostate-specific antigen (PSA) failure after radical prostatectomy (RP) in men with rapid rises in PSA doubling time (DT, < 6 months). Whether such a benefit exits in ...
Full textLink to itemCite
Journal ArticleJ Urol · July 2011
Featured Publication
PURPOSE: Radical prostatectomy and brachytherapy are widely used treatments for favorable risk prostate cancer. We estimated the risk of prostate cancer specific mortality following radical prostatectomy or brachytherapy in men with low or intermediate ris ...
Full textLink to itemCite
Journal ArticleBJU Int · July 2011
Featured Publication
OBJECTIVE: • To evaluate weather prostate-specific antigen (PSA) velocity could be used to stratify patients at risk of death from prostate cancer (PCa) and be useful in aiding decision making regarding PSA screening in elderly men, as previous studies hav ...
Full textLink to itemCite
Journal ArticleJ Clin Oncol · May 20, 2011
4664 Background: Sunitinib malate (Sutent, Pfizer) is an oral multi-targeted tyrosine kinase inhibitor of VEGF/PDGF receptors that may function in part to inhibit prostate tumor growth via anti-angiogenic mechanisms. METHODS: We conducted a multi-site stud ...
Link to itemCite
Journal ArticleJ Clin Oncol · May 20, 2011
e19617 Background: Little is known about physicians' (MDs) and cancer patients' (pts) levels of awareness or concern about bone health or how/when MDs discuss bone health with at-risk patients. An online survey was conducted to explore these issues and eva ...
Link to itemCite
OtherBJU Int · April 2011
Key controversies concerning the management of genitourinary cancers across the treatment continua were discussed at the second annual Interactive Genitourinary Cancer Conference (IGUCC) held in February 2010 in Athens, Greece. Prostate cancer is the most ...
Full textLink to itemCite
Journal ArticleJournal of Clinical Oncology · March 1, 2011
198 Background: Radical prostatectomy (RP) and brachytherapy (BT) are widely utilized treatments for favorable-risk prostate cancer (PC). We estimated the risk of PC-specific mortality (PCSM) following RP or BT in men with low- o ...
Full textCite
ConferenceJournal of Clinical Oncology · March 1, 2011
47 Background: ProsVue is an investigational PSA immunoassay whose reporter antibody is labeled with a synthetic DNA sequence. RT-PCR detects the DNA signal indicating the PSA concentration. Pilot studies showed ProsVue slope (le ...
Full textCite
ConferenceJournal of Clinical Oncology · March 1, 2011
12 Background: Comparative effectiveness of the gonadotropin-releasing hormone (GnRH) blocker, degarelix, vs the GnRH agonist, leuprolide, was evaluated during a 1-year phase III trial (CS21); data have been presented. We now rep ...
Full textCite
Journal ArticleJ Clin Oncol · March 2011
117 Background: Endothelin-1 and the endothelin A (ETA) receptor have been implicated in prostate cancer progression in bone. Zibotentan, a specific ETA receptor antagonist, had a promising signal for prolonged overall survival (OS) in a phase II study of ...
Link to itemCite
Journal ArticleJ Clin Oncol · March 2011
198 Background: Radical prostatectomy (RP) and brachytherapy (BT) are widely utilized treatments for favorable-risk prostate cancer (PC). We estimated the risk of PC-specific mortality (PCSM) following RP or BT in men with low- or intermediate-risk PC usin ...
Link to itemCite
Journal ArticleJ Clin Oncol · March 2011
12 Background: Comparative effectiveness of the gonadotropin-releasing hormone (GnRH) blocker, degarelix, vs the GnRH agonist, leuprolide, was evaluated during a 1-year phase III trial (CS21); data have been presented. We now report long-term data from an ...
Link to itemCite
Journal ArticleJ Clin Oncol · March 2011
47 Background: ProsVue is an investigational PSA immunoassay whose reporter antibody is labeled with a synthetic DNA sequence. RT-PCR detects the DNA signal indicating the PSA concentration. Pilot studies showed ProsVue slope (least-squares linear slope of ...
Link to itemCite
Journal ArticleJ Urol · March 2011
Featured Publication
PURPOSE: Improvement in the cost-effectiveness of chemoprevention for prostate cancer could be realized through the identification of patients at higher risk. We estimated the cost-effectiveness of prostate cancer chemoprevention across risk groups defined ...
Full textLink to itemCite
Journal ArticleProstate Cancer · 2011
Featured Publication
Purpose. Patients diagnosed with clinically localized prostate cancer have more surgical treatment options than in the past. This paper focuses on the procedures' oncological or functional outcomes and perioperative morbidities of radical retropubic prosta ...
Full textOpen AccessLink to itemCite
Journal ArticleBJU Int · December 2010
Featured Publication
OBJECTIVE: To determine the adequacy of T2 prostate cancer (PCa) sub-staging as an independent Predictor of biochemical disease-free survival (bDFS) after radical prostatectomy. MATERIALS AND METHODS: The Duke Prostate Center database was queried for patie ...
Full textLink to itemCite
Journal ArticleBJU Int · December 2010
Featured Publication
OBJECTIVE: To investigate whether salvage radiation therapy (RT) for prostate-specific antigen (PSA) failure can provide the same result as adjuvant RT, which decreases the risk of all-cause mortality (ACM) for men with positive margins (R1), or extra-caps ...
Full textLink to itemCite
Journal ArticleInt J Urol · November 2010
OBJECTIVES: We previously showed that prostate-specific antigen (PSA) nadir after radical prostatectomy (RP) significantly predicts biochemical recurrence (BCR). Herein, we sought to explore the effect of including PSA nadir into commonly used models on th ...
Full textLink to itemCite
Journal ArticleUrology · November 2010
OBJECTIVES: To evaluate the relationship between initial prostate-specific antigen (PSA) and prostate cancer (PCa) risk in elderly African American (AA) and Caucasian American (CA) men. METHODS: A total of 408 AA and 1720 CA men whose initial PSA measureme ...
Full textLink to itemCite
Journal ArticleCancer · October 15, 2010
Featured Publication
BACKGROUND: A diagnosis of prostate cancer is not often predictive of death from prostate cancer because of competing causes of mortality. Identification of the risk of death from prostate cancer and death from all causes using information available at the ...
Full textLink to itemCite
Journal ArticlePathol Int · October 2010
Featured Publication
The objective of this study was to assess the incidence of circulating tumor cells (CTCs) in prostate cancer patients with low-volume tumors (less than 0.5 cc) after radical prostatectomy (RP). Blood samples were collected from 64 RP patients to assess the ...
Full textLink to itemCite
Journal ArticleBJU Int · October 2010
Featured Publication
OBJECTIVE: to analyse the relationship between African American (AA) race and obesity in men with prostate cancer. PATIENTS AND METHODS: in all, 4196 patients who underwent radical prostatectomy from 1988 to 2008 were identified in the Duke Prostate Center ...
Full textLink to itemCite
Journal ArticleBJU Int · September 2010
OBJECTIVE: To validate a model previously developed using the Shared Equal Access Regional Cancer Hospital (SEARCH) database to predict the risk of aggressive recurrence after surgery, defined as a prostate-specific antigen (PSA) doubling time (DT) of <9 m ...
Full textLink to itemCite
Journal ArticleProstate Cancer Prostatic Dis · September 2010
Featured Publication
The objective of this study was to preoperatively predict non-organ-confined disease in patients considering radical prostatectomy. To account for the stage migration seen in prostate cancer, we included only those patients who underwent prostatectomy afte ...
Full textLink to itemCite
Journal ArticleBJU Int · August 2010
Featured Publication
Prostate cancer is the most prevalent cancer in men and predominantly affects older men (aged >or=70 years). The median age at diagnosis is 68 years; overall, two-thirds of prostate cancer-related deaths occur in men aged >or=75 years. With the exponential ...
Full textOpen AccessLink to itemCite
Journal ArticleOncology (Williston Park) · July 2010
BACKGROUND: A 36-year-old male with a history of cryptorchidism of the right side, treated with orchidopexy at the age of 4, presented with bilateral testicular swelling. INVESTIGATIONS: Investigations included laboratory workup, ultrasound of both testes, ...
Link to itemCite
Journal ArticleBJU Int · July 2010
Study Type - Therapy (RCT) Level of Evidence 1b OBJECTIVE To compare the activity of degarelix, a new gonadotrophin-releasing hormone (GnRH) blocker, with leuprolide depot 7.5 mg in the control of total serum alkaline phosphatase (S-ALP) levels in patients ...
Full textLink to itemCite
Journal ArticleBJU Int · June 2010
Featured Publication
OBJECTIVE: To re-calibrate the previously published Duke Prostate Center (DPC) nomogram for the prediction of biochemical recurrence (BCR) after radical prostatectomy (RP) to not only predict overall BCR but also the clinically more relevant endpoint of an ...
Full textLink to itemCite
Journal ArticleJ Endourol · May 2010
Featured Publication
Since at least the early 1990s, stage and risk migration have been seen in patients with prostate cancer, likely corresponding to the institution of prostate specific antigen (PSA) screening in health systems. Preoperative risk factors, including PSA level ...
Full textOpen AccessLink to itemCite
Journal ArticleUrology · May 2010
Featured Publication
OBJECTIVES: To evaluate the US Preventative Services Task Force (USPSTF) recommendation to discontinue prostate-specific antigen (PSA) screening at age 75. METHODS: Public survey: A cohort of 340 patients was surveyed at our PSA screening clinic and strati ...
Full textLink to itemCite
Journal ArticleEur Urol · May 2010
BACKGROUND: Recent data suggest prostate-specific antigen (PSA) progression may predict overall survival in prostate cancer patients. OBJECTIVE: To compare the activity of degarelix and leuprolide regarding PSA recurrence-free survival. DESIGN, SETTING, AN ...
Full textLink to itemCite
Journal ArticleCancer · April 15, 2010
BACKGROUND: This report evaluated whether biochemical recurrence (BCR) as a time-dependent covariate (t) after radical prostatectomy (RP) for prostate cancer was associated with the risk of death and whether salvage therapy with radiotherapy (RT) and/or ho ...
Full textLink to itemCite
Journal ArticleProstate Cancer Prostatic Dis · March 2010
Featured Publication
To evaluate whether race modifies the accuracy of nomograms to predict biochemical recurrence (BCR) after radical prostatectomy among subjects from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center (DPC) databases. Retrospe ...
Full textLink to itemCite
Journal ArticleJ Urol · March 2010
Featured Publication
PURPOSE: Studies show that initial prostate specific antigen higher than the median in young men predicts a subsequent higher risk of prostate cancer. To our knowledge this relationship has not been studied in patients stratified by race. MATERIALS AND MET ...
Full textLink to itemCite
Journal ArticleJ Urol · March 2010
Featured Publication
PURPOSE: We determined the predictive power of tumor percent involvement on prostate specific antigen recurrence in patients when stratified by prostate weight. MATERIALS AND METHODS: Data on 3,057 patients who underwent radical prostatectomy between 1988 ...
Full textLink to itemCite
Journal ArticleUrology · February 2010
Featured Publication
OBJECTIVES: To compare the effects of tumor volume (TV), tumor percentage involvement (TPI), and prostate volume (PV) on prostate-specific antigen (PSA) recurrence (PSAR) after radical prostatectomy (RP). METHODS: A cohort of 3528 patients receiving RP bet ...
Full textLink to itemCite
Journal ArticleCrit Rev Oncol Hematol · January 2010
Featured Publication
BACKGROUND: The incidence of prostate cancer increases with age, with a median age at diagnosis of 68 years. Owing to increased life expectancy, the management of prostate cancer in senior adult men (i.e., aged 70 years or older) represents an important pu ...
Full textLink to itemCite
Journal ArticleUrology · November 2009
Featured Publication
OBJECTIVES: To compare Gleason scores (GS) originally assigned in the mid 1990s with the current pathologic evaluation of the same prostatectomy slides, and to assess the GS migration effect on outcome in patients undergoing surgical treatment of prostate ...
Full textLink to itemCite
Journal ArticleJ Urol · November 2009
Featured Publication
PURPOSE: We clarified whether men older than 70 years have a higher risk of prostate cancer and poorer survival in the early and late prostate specific antigen eras. MATERIALS AND METHODS: A cohort of 4,561 men who underwent radical prostatectomy were stra ...
Full textLink to itemCite
Journal ArticleBJU Int · November 2009
Featured Publication
OBJECTIVE: To compare open radical prostatectomy (RP) and robot-assisted laparoscopic prostatectomy (RALP), and to determine whether RALP is associated with a higher risk of features that determine recommendations for postoperative radiation therapy (RT). ...
Full textLink to itemCite
Journal ArticleAging Health · September 18, 2009
Over the past two decades, prostate-specific antigen has become the primary modality for prostate cancer screening and has led to earlier detection. However, the question remains as to whether earlier detection actually leads to reductions in prostate canc ...
Full textCite
Journal ArticleTher Adv Med Oncol · September 2009
Prostate cancer (PCa) is the most common type of cancer found in American men, other than skin cancer. The American Cancer Society estimates that there will be 186,320 new cases of prostate cancer in the United States in 2008. About 28,660 men will die of ...
Full textLink to itemCite
Journal ArticleUrology · September 2009
Featured Publication
OBJECTIVES: To identify factors that predict delayed (> 5 years) prostate-specific antigen recurrence (PSAR) after radical prostatectomy (RP) and to analyze the associated clinical outcomes. METHODS: A cohort of 4561 men who underwent RP between 1988 and 2 ...
Full textLink to itemCite
Journal ArticleUrology · September 2009
Featured Publication
OBJECTIVES: To clarify the relationship between age and pathologic Gleason score and their effect on prostate-specific antigen recurrence (PSAR). METHODS: The data from a cohort of 2911 men who had undergone radical prostatectomy from 1988 to 2006 were ret ...
Full textLink to itemCite
Journal ArticleJ Urol · August 2009
Featured Publication
PURPOSE: Preoperative prostate specific antigen is widely used to predict unfavorable pathological features and biochemical relapse after radical prostatectomy. Recent reports that hemodilution may be responsible for lower prostate specific antigen in obes ...
Full textLink to itemCite
Journal ArticleBJU Int · August 2009
Featured Publication
OBJECTIVE: To compare the efficacy and tolerability of peripheral androgen blockade using combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for treating biochemical relapse after the definitive management of prostate adenocarci ...
Full textLink to itemCite
Journal ArticleJ Clin Anesth · August 2009
Featured Publication
STUDY OBJECTIVE: To compare anesthetic management and postoperative outcomes in patients undergoing robot-assisted laparoscopic radical prostatectomy (RALP) and radical retropubic prostatectomy (RRP) with general anesthesia. DESIGN: Retrospective database ...
Full textLink to itemCite
Journal ArticleMed Image Anal · August 2009
Prostate biopsy is the current gold-standard procedure for prostate cancer diagnosis. Existing prostate biopsy procedures have been mostly focusing on detecting cancer presence. However, they often ignore the potential use of biopsy to estimate cancer volu ...
Full textLink to itemCite
Journal ArticleJ Urol · July 2009
Featured Publication
PURPOSE: We determined clinical factors affecting the under grading of biopsy Gleason sum compared with prostatectomy pathology and developed a model predicting the probability of under grading. MATERIALS AND METHODS: We analyzed a cohort of 1,701 patients ...
Full textLink to itemCite
Journal ArticleAnesth Analg · June 2009
Featured Publication
In a prospective, double-blind, placebo-controlled study, patients undergoing radical retropubic prostatectomy under general anesthesia were randomly assigned to receive a lidocaine patch or placebo applied on each side of the wound at the end of surgery. ...
Full textLink to itemCite
Journal ArticleCancer · May 15, 2009
Featured Publication
BACKGROUND: The application of focal therapy for low-risk prostate cancer (PCa) depended on appropriate patient selection. No definitive criteria existed to characterize patients who may potentially benefit from an organ-sparing approach. We evaluated pret ...
Full textLink to itemCite
Journal ArticleTechnol Cancer Res Treat · April 2009
Featured Publication
The 3-D transrectal ultrasound (TRUS)-guided prostate biopsy system is a novel device that allows precise needle placement in a template fashion. We evaluate its utility for prostate cancer (PCa) detection. A retrospective analysis was performed evaluating ...
Full textLink to itemCite
Journal ArticleInt J Radiat Oncol Biol Phys · March 1, 2009
Featured Publication
PURPOSE: To determine whether the number of unfavorable risk factors could be used to predict the risk of prostate cancer-specific mortality (PCSM) among men with intermediate- to high-risk prostate cancer. METHODS AND MATERIALS: We studied 1,063 men who u ...
Full textLink to itemCite
Journal ArticleCurr Opin Urol · March 2009
Featured Publication
PURPOSE OF REVIEW: This review highlights current features of the changing landscape of the US population with newly diagnosed prostate cancer and discusses new treatment options utilizing noninvasive or minimally invasive management. RECENT FINDINGS: Rece ...
Full textLink to itemCite
Journal ArticleUrol Oncol · 2009
Featured Publication
The screening zeal for prostate cancer in the PSA era resulted in and continues to produce an unprecedented number of men who have clinically localized prostate cancer seeking radical prostatectomy. Even before the advent of robotic laparoscopic-assisted r ...
Full textLink to itemCite
Journal ArticleProstate Cancer Prostatic Dis · 2009
Featured Publication
Obesity is associated with increased risk of positive surgical margins and prostate specific antigen (PSA) recurrence among men undergoing radical prostatectomy. To what degree positive margins contribute to poorer outcome is unclear. Thus, we sought to ex ...
Full textLink to itemCite
Journal ArticleCancer Epidemiol Biomarkers Prev · December 2008
Featured Publication
BACKGROUND: Prostate cancer affects one of six men during their lifetime. Dietary factors are postulated to influence the development and progression of prostate cancer. Low-fat diets and flaxseed supplementation may offer potentially protective strategies ...
Full textLink to itemCite
Journal ArticleCancer · November 15, 2008
Featured Publication
BACKGROUND: Both the 5-item short version of the International Index of Erectile Function (IIEF-5) and the Expanded Prostate Cancer Index Composite (EPIC) have been used to assess erectile function. In this study, the authors compared various definitions o ...
Full textLink to itemCite
Journal ArticleUrology · October 2008
Featured Publication
OBJECTIVES: To assess the discrepancies between diagnostic and pathologic Gleason sums and the predictive role of age and prostate-specific antigen (PSA) level on Gleason sum discrepancies. METHODS: A total of 2963 patients receiving radical prostatectomy ...
Full textLink to itemCite
Journal ArticleCrit Rev Oncol Hematol · October 2008
A multidisciplinary panel of 20 international experts, including urologists, radiation oncologists, and medical oncologists, convened during the Advanced Prostate Cancer Multidisciplinary Team meeting in Rome, Italy, in January 2007, to discuss the multidi ...
Full textLink to itemCite
Journal ArticleProstate · September 15, 2008
Featured Publication
BACKGROUND: Early detection of small volume prostate cancer (PCa) has led to the concept of focal therapy to treat in an organ-sparing manner. We evaluated trends in pathologic staging among patients with localized PCa undergoing radical prostatectomy (RP) ...
Full textLink to itemCite
Journal ArticleCancer · September 15, 2008
Featured Publication
BACKGROUND: Disagreement exists on the use of prostate-specific antigen (PSA) tests for cancer-risk stratification in young men in the United States. Little is known about the use of PSA testing in these men. To understand policy implications of risk strat ...
Full textLink to itemCite
Journal ArticleAnesth Analg · September 2008
Featured Publication
BACKGROUND: Previous animal and human studies suggested that nicotine might have an antinociceptive effect. We hypothesized that the preoperative application of a 7 mg nicotine patch would result in reduced postoperative analgesic requirements in patients ...
Full textLink to itemCite
Journal ArticleBJU Int · September 2008
Featured Publication
OBJECTIVE: To indirectly test the hypothesis that prostate-specific antigen (PSA)-based screening is biased against obese men due to haemodilution of PSA, and thus results in delayed diagnosis and poorer outcome beyond the biological link between obesity a ...
Full textLink to itemCite
Journal ArticleJ Urol · August 2008
Featured Publication
PURPOSE: Percent tumor involvement has been associated with biochemical progression in organ confined disease, although its role in predicting outcome in men with more advanced disease pathology is unclear. We hypothesized percent tumor involvement may be ...
Full textLink to itemCite
Journal ArticleJ Natl Black Nurses Assoc · July 2008
Featured Publication
There is minimal research regarding men's knowledge of the limitations of prostate cancer screening. This study measured knowledge of prostate cancer screening based on exposure to one of two decision aids that were related to prostate cancer screening (en ...
Link to itemCite
Journal ArticleBJU Int · July 2008
Featured Publication
OBJECTIVES: To compare the prostate-specific antigen (PSA) recurrence (PSAR) rates in patients undergoing robot-assisted laparoscopic radical prostatectomy (RALP) or radical retropubic prostatectomy (RRP). PATIENTS AND METHODS: Data from 797 consecutive pa ...
Full textLink to itemCite
Journal ArticleUrology · June 2008
Featured Publication
OBJECTIVES: We evaluated the lower threshold of prostate-specific antigen (PSA) and prostate-specific antigen velocity (PSAV) in a population of men over 70 years of age. METHODS: Between January 1988 and December 2005, 4038 men over 70 years of age includ ...
Full textLink to itemCite
Journal ArticleInt J Radiat Oncol Biol Phys · June 1, 2008
PURPOSE: The (111)In-capromab pendetide scan (ProstaScint; Cytogen Corp., Princeton NJ) is approved by the Food and Drug Administration to evaluate increasing prostate-specific antigen (PSA) levels after radical prostatectomy. This study evaluated the role ...
Full textLink to itemCite
Journal ArticleJ Clin Oncol · May 20, 2008
16002 Background: Several formulations of Luteinizing Hormone-Releasing Hormone Agonists (LHRH-A) of varying duration are available for treatment of prostate cancer (PCa). Previous reports suggest that utilization of longer acting LHRH-A may reduce the num ...
Link to itemCite
Journal ArticleJ Urol · May 2008
Featured Publication
PURPOSE: Hormonal therapy (HT) is the current mainstay of systemic treatment for prostate specific antigen (PSA) only recurrence (PSAR), however, there is virtually no published literature comparing HT to observation in the clinical setting. The goal of th ...
Full textLink to itemCite
Journal ArticleUrology · April 2008
Featured Publication
OBJECTIVES: We evaluated the learning curves and perioperative outcomes of an experienced laparoscopic surgeon and his trainees to assess our structured teaching program. METHODS: We retrieved 383 patients undergoing robot-assisted laparoscopic prostatecto ...
Full textLink to itemCite
Journal ArticleJ Urol · February 2008
Featured Publication
PURPOSE: The Gleason grading system in reporting prostate cancer accounts for the primary and secondary Gleason pattern. The clinical significance of a higher tertiary (third most prevalent) grade is largely unrecognized. MATERIALS AND METHODS: Radical pro ...
Full textLink to itemCite
Journal ArticleProstate Cancer Prostatic Dis · 2008
Featured Publication
We hypothesized that factors beyond pathological stage, grade, PSA and margin status would be important predictors of biochemical recurrence (BCR) after radical prostatectomy (RP). A cohort of 3194 patients who underwent RP between 1988 and 2007 and who ha ...
Full textLink to itemCite
Journal ArticleUrology · December 2007
Featured Publication
OBJECTIVES: Baby Boomers (those born in 1946 to 1964) are thought to place a high value on quality of life, and have a higher propensity to consume healthcare services than previous generations. We sought to characterize prostate cancer (CaP) presentation ...
Full textLink to itemCite
Journal ArticleUrology · December 2007
Featured Publication
OBJECTIVES: To examine the association between body mass index (BMI) and operative time, estimated blood loss (EBL), and adverse pathologic features in patients undergoing either radical perineal prostatectomy (RPP) or radical retropubic prostatectomy (RRP ...
Full textLink to itemCite
Journal ArticleUrology · December 2007
Featured Publication
OBJECTIVES: To evaluate biologic behaviors of unilateral cancers compared with bilateral cancers on prostate-specific antigen (PSA) recurrence after radical prostatectomy. METHODS: Analysis included demographic, clinical, and pathologic parameters of 1184 ...
Full textLink to itemCite
Journal ArticleJAMA · November 21, 2007
Featured Publication
CONTEXT: Recent studies have suggested that obese men have lower serum prostate-specific antigen (PSA) concentrations than nonobese men. Because men with higher body mass index (BMI) have greater circulating plasma volumes, lower PSA concentrations among o ...
Full textLink to itemCite
Journal ArticleOncology (Williston Park) · November 2007
Featured Publication
Rising prostate-specific antigen (PSA) in nonmetastatic prostate cancer occurs in two main clinical settings: (1) rising PSA to signal failed initial local therapy and (2) rising PSA in the setting of early hormone-refractory prostate cancer prior to docum ...
Link to itemCite
Journal ArticleExpert Rev Anticancer Ther · September 2007
Featured Publication
The introduction of robotic laparoscopic assisted prostatectomy at our institution and nationwide has been a great advancement and has caused us to focus and fine-tune our goal for improvements in prostate cancer outcomes whether the patient elects for rob ...
Full textLink to itemCite
Journal ArticleCancer · August 15, 2007
Featured Publication
BACKGROUND: Early detection of small-volume prostate cancer (PCa) has led to the concept of focal therapy to treat PCa as an organ-sparing, minimally invasive procedure. The authors sought to determine the frequency of unilateral cancers in the contemporar ...
Full textLink to itemCite
Journal ArticleJournal of the National Comprehensive Cancer Network · August 2007
Prostate cancer is the most commonly diagnosed cancer in American men and the third leading cause of cancer-related deaths. However, the decision whether to pursue early detection of prostate cancer is complex; because not all men with prostate can ...
Full textCite
Journal ArticleJ Urol · August 2007
Featured Publication
PURPOSE: In conjunction with the assignment to update the Guidelines for Management of Clinically Localized Prostate Cancer, the American Urological Association Prostate Cancer Guideline Update Panel performed a side analysis of the reporting of erectile f ...
Full textLink to itemCite
Journal ArticleCancer · July 1, 2007
Featured Publication
BACKGROUND: Estimates of prostate cancer-specific mortality (PCSM) were determined after radical prostatectomy (RP) or radiation therapy (RT) in men with >or=1 high-risk factors. METHODS: The study cohort comprised 948 men who underwent RP (N = 660) or RT ...
Full textLink to itemCite
Journal ArticleJ Urol · June 2007
Featured Publication
PURPOSE: We estimate that approximately 70,000 men yearly have prostate specific antigen-only recurrence after failed definitive therapy. The ideal salvage therapy for these men is not clear. Treatment must be individualized based on the patient risk of pr ...
Full textLink to itemCite
Journal ArticleIEEE Trans Med Imaging · June 2007
In this paper, a method for maximizing the probability of prostate cancer detection via biopsy is presented, by combining image analysis and optimization techniques. This method consists of three major steps. First, a statistical atlas of the spatial distr ...
Full textLink to itemCite
Journal ArticleCurr Urol Rep · May 2007
Featured Publication
Radical retropubic prostatectomy and radiation therapy remain the mainstay of treatment for localized prostate cancer. However, with the advent of the Internet, more patients are arriving in physicians' offices questioning novel techniques for their treatm ...
Full textLink to itemCite
Journal ArticleUrol Clin North Am · May 2007
Featured Publication
Early detection of testicular tumors has been touted as beneficial for more than 100 years. In earlier eras, early detection was virtually the only way to improve outcomes. According to statistics that have been tracked in the literature, however, the dela ...
Full textLink to itemCite
Journal ArticleJ Urol · April 2007
Featured Publication
PURPOSE: We determined the potential influence of an early adopter bias in patients undergoing robot assisted laparoscopic prostatectomy. MATERIALS AND METHODS: We compared baseline demographic, clinical and health related quality of life characteristics o ...
Full textLink to itemCite
Journal ArticleBJU Int · April 2007
Featured Publication
OBJECTIVE: To identify threshold values of prostate-specific antigen (PSA) levels and PSA velocity (PSAV) to optimize the assessment of the risk of prostate cancer in young men, as prostate cancer is detected increasingly in men aged <50 years. PATIENTS AN ...
Full textLink to itemCite
Journal ArticleMinerva Urol Nefrol · March 2007
Systemic therapy beyond hormonal therapy for advanced prostate cancer includes chemotherapy, antiangiogenic therapy, signal transduction inhibitors, immunomodulatory therapy, and other experimental therapeutics. This review will discuss the state of system ...
Link to itemCite
Journal ArticleExpert Rev Med Devices · March 2007
Featured Publication
Prostate cancer is an extremely prevalent problem, especially in our aging population. The prostate-specific antigen test has revolutionized prostate cancer screening. Significant advances have been made in the usage of prostate-specific antigen and its de ...
Full textLink to itemCite
Journal ArticleJ Urol · February 2007
Featured Publication
PURPOSE: The American Urological Association Prostate Guideline Update Panel was charged with updating the Guidelines for Clinically Localized Prostate Cancer. In assessing outcomes with treatment, it became apparent that a highly variable number of defini ...
Full textLink to itemCite
Journal ArticleJ Urol · February 2007
Featured Publication
PURPOSE: Obesity is associated with more advanced disease and worse outcomes in men with prostate cancer. To our knowledge the relationship between obesity and prostate cancer screening behavior in men 40 or older is unknown. Thus, we examined associations ...
Full textLink to itemCite
Journal ArticleUrology · February 2007
Featured Publication
OBJECTIVES: To evaluate the financial implications of how the costs of new minimally invasive surgery such as laparoscopic robotic prostatectomy (LRP) and cryosurgical ablation of the prostate (CAP) technologies compare with those of conventional surgery. ...
Full textLink to itemCite
Journal ArticleJ Urol · February 2007
Featured Publication
PURPOSE: We identified age adjusted prostate specific antigen and prostate specific antigen velocity cut points for prostate cancer biopsy. MATERIALS AND METHODS: A cohort of 33,643 men was retrieved from the Duke Prostate Center database. Of this group 11 ...
Full textLink to itemCite
OtherConsultant · December 1, 2006
Prostaste-specific antigen (PSA) recurrence is the most common form of advanced prostate cancer. Salvage therapies may be effective even among some high-risk men, although long-term cancer control data are limited The natural history of PSA recurrence is l ...
Cite
Journal ArticleDNA Cell Biol · November 2006
Featured Publication
The long arm of chromosome 6 is frequently deleted in diverse human neoplasms. Our previous study showed a minimum deletion region between markers D6S1056 and D6S300 on chromosome 6q in primary prostate cancer (CaP). In this study, we further refined a 200 ...
Full textLink to itemCite
Journal ArticleUrology · August 2006
Featured Publication
OBJECTIVES: To compare the preoperative characteristics, postoperative prostate-specific antigen (PSA) doubling time (DT), and prostate cancer-specific mortality (PCSM) estimates after PSA failure in men diagnosed during a screening study versus a communit ...
Full textLink to itemCite
Journal ArticleHematol Oncol Clin North Am · August 2006
Featured Publication
PSA-only recurrence after definitive RP or RT for PCA is an increasingly com-mon scenario. The very definition of advanced prostate cancer is changing. Multimodal therapy improves cancer-specific outcomes especially in men with high-risk disease. After RP, ...
Full textLink to itemCite
Journal ArticleJ Urol · August 2006
Featured Publication
PURPOSE: Although there is general agreement that men older than 75 years are unlikely to benefit from prostate specific antigen testing, patient reported testing rates in these patients exceed 30%. We examined physician reported PSA testing in elderly men ...
Full textLink to itemCite
Journal ArticleOncol Rep · July 2006
Featured Publication
In order to evaluate the molecular heterogeneity of prostate cancer, this study examined the expression of Akt-pathway related parameters within the cancerous prostate gland. PTEN, p-Akt and p27kip1 are known to be altered in prostate cancer. Tissue sample ...
Link to itemCite
Journal ArticleUrology · July 2006
OBJECTIVES: To perform a nationwide survey of urologists' opinions and behavior regarding the use of prostate-specific antigen (PSA) in prostate cancer follow-up and secondary treatment. METHODS: A random sample of 300 urologists was interviewed. Content a ...
Full textLink to itemCite
Journal ArticleCurr Opin Urol · May 2006
Featured Publication
PURPOSE OF REVIEW: The purpose of this review is to summarize single-institution prostate-cancer-outcomes databases (which are most commonly derived from large academic medical centers, Veterans Affairs medical centers, and military hospitals) to summarize ...
Full textLink to itemCite
Journal ArticleCurr Pharm Des · 2006
Featured Publication
Prostate cancer recurrence (after prior local treatment) that is detectable only by a rise in serum prostate specific antigen (PSA) level is a very common problem facing clinicians. Given that the majority of contemporary era men with PSA-only or biochemic ...
Full textLink to itemCite
Journal ArticleProstate Cancer Prostatic Dis · 2006
Featured Publication
A 65-year-old man with a history of combined pelvic external beam radiation therapy (EBRT) and brachytherapy for prostatic adenocarcinoma 15 years prior underwent total pelvic exenteration for presumed rectal sarcoma with prostatic invasion. Pathology reve ...
Full textLink to itemCite
Journal ArticleProstate Cancer Prostatic Dis · 2006
Featured Publication
PSGR is a novel member of the G-protein-coupled olfactory receptor family. Our initial report showed predominant expression of the PSGR in human prostate gland and significant alterations of PSGR expression in primary prostate cancer (CaP) specimens. The a ...
Full textLink to itemCite
Journal ArticleProstate Cancer Prostatic Dis · 2006
Featured Publication
To determine the timing and patterns of late recurrence after radical prostatectomy (RP) alone or RP plus adjuvant radiotherapy (RT). Between 1970 and 1983, 159 patients underwent RP for newly diagnosed adenocarcinoma of the prostate and were found to have ...
Full textLink to itemCite
Journal ArticleUrology · December 2005
Featured Publication
OBJECTIVES: To compare prostate-specific antigen (PSA) and PSA density (PSAD) calculated by transrectal ultrasound (TRUS) volume (TRUS PSAD), pathologic volume (Path PSAD), and weight (Weight PSAD) for their ability to predict pathologic characteristics an ...
Full textLink to itemCite
Journal ArticleJ Clin Oncol · November 10, 2005
Featured Publication
Prostate cancer remains the most common noncutaneous human malignancy, and the second most lethal tumor among men. However, the natural history of the disease is often prolonged, and the survival benefits of local therapy for men with low-risk tumors may n ...
Full textLink to itemCite
Journal ArticleMil Med · November 2005
Featured Publication
With the widespread use of the prostate-specific antigen (PSA) test, smaller cancers are being detected among younger men and 5-year, cancer-specific, survival rates are on the rise. Although this lead-time effect may not translate into long-term improveme ...
Full textLink to itemCite
Journal ArticleJ Clin Oncol · October 1, 2005
Featured Publication
PURPOSE: We evaluated predictors of prostate cancer-specific mortality (PCSM) after prostate-specific antigen (PSA) failure after radical prostatectomy (RP) or radiation therapy (RT). PATIENTS AND METHODS: A total of 1,159 men with clinically localized pro ...
Full textLink to itemCite
Journal ArticleJ Clin Oncol · September 20, 2005
Featured Publication
PURPOSE: For men receiving androgen-suppression therapy (AST) for a rising postoperative or postradiation prostate-specific antigen (PSA), we evaluated whether a PSA nadir of more than 0.2 ng/mL was significantly associated with prostate cancer-specific mo ...
Full textLink to itemCite
Journal ArticleJ Urol · July 2005
Featured Publication
PURPOSE: We assessed the feasibility of radical perineal prostatectomy (RPP) in morbidly obese patients with clinically organ confined prostate cancer. MATERIALS AND METHODS: Of 1,265 consecutive patients who underwent RPP at our institution from 1992 to 2 ...
Full textLink to itemCite
Journal ArticleJ Clin Oncol · June 2005
4548 Background: PSA-defined recurrence as far out as 10 years following radical prostatectomy (RP) or radiation therapy (RT) for men with clinically localized prostate cancer occurs in up to 30% of cases. Yet a minority of these men will experience prosta ...
Link to itemCite
Journal ArticleCan J Urol · June 2005
Featured Publication
We currently lack a prospective, randomized, multicenter trial, to reassure low-risk prostate cancer patients, especially younger ones, that watchful waiting is a legitimate treatment. To better manage these patients, we need to: first, confirm that the pa ...
Link to itemCite
Journal ArticleClin Prostate Cancer · June 2005
Featured Publication
As increasing numbers of men are living longer with prostate cancer, larger proportions will eventually present to our collective practices with increasing prostate-specific antigen (PSA) levels. Such PSA relapses, conservatively estimated to affect approx ...
Full textLink to itemCite
Journal ArticleOncogene · May 26, 2005
Featured Publication
Transcription factors encoded by the ETS family of genes are central in integrating signals that regulate cell growth and differentiation, stress responses, and tumorigenesis. This study, analysing laser microdissected paired benign and malignant prostate ...
Full textLink to itemCite
Journal ArticleCurr Opin Urol · May 2005
Featured Publication
PURPOSE OF REVIEW: State-of-the-art proteomics technologies are currently being assessed for utility in the study of prostatic malignancy. This review aims to provide background information on the current proteomics techniques employed in prostate cancer r ...
Full textLink to itemCite
Journal ArticleCurr Opin Urol · May 2005
Featured Publication
PURPOSE OF REVIEW: Through the prostate-specific antigen era, the proportion of men less than 55 years old with newly diagnosed prostate cancer more than doubled to almost 15%. As increasing numbers of men are living longer with prostate cancer, larger pro ...
Full textLink to itemCite
Journal ArticleCurr Opin Urol · May 2005
Featured Publication
PURPOSE OF REVIEW: The introduction of prostate-specific antigen into clinical practice heralded a dramatic shift in the epidemiology of prostate cancer. The diagnosis and treatment of lower stage disease in younger men with fewer competing co-morbidities ...
Full textLink to itemCite
Journal ArticleJ Urol · May 2005
PURPOSE: We determined whether prostate specific antigen (PSA) velocity can serve as surrogate end point for prostate cancer specific mortality (PCSM) in patients with nonmetastatic, hormone refractory prostate cancer. MATERIALS AND METHODS: The study coho ...
Full textLink to itemCite
Journal ArticleNat Clin Pract Urol · April 2005
Featured Publication
An estimated 20-40% of men experience a biochemical recurrence within 10 years of definitive prostate cancer treatment. No single prostate-specific antigen (PSA) value is invariably associated with clinical metastasis or cancer-specific survival; PSA kinet ...
Full textLink to itemCite
Chapter · January 1, 2005
What we presently know about the disease entity known as prostate cancer has grown tremendously since the first documented case by Langstaff in 1815.1 Accumulation of knowledge since the mid-1980s has risen logarithmically, bolstered by the advancement of ...
Cite
Journal ArticleClin Chem · January 2005
Featured Publication
BACKGROUND: Protein expression profiling for differences indicative of early cancer has promise for improving diagnostics. This report describes the first stage of a National Cancer Institute/Early Detection Research Network-sponsored multiinstitutional ev ...
Full textLink to itemCite
Journal ArticleAnticancer Res · 2005
Featured Publication
The generation of suitable in vitro models is critical for understanding the process associated with the development and progression of prostate cancer in high-risk African-American men. However, the generation of long-term human prostate epithelial cell l ...
Link to itemCite
Journal ArticleInt J Oncol · December 2004
The HER2/neu protein is over-expressed in multiple epithelial tumors and the source of immunogenic peptides currently under investigation in vaccine trials in ovarian and breast cancers. We sought to define the correlation between HER2/neu expression and r ...
Link to itemCite
Journal ArticleJ Urol · November 2004
PURPOSE: A short posttreatment prostate specific antigen (PSA)-doubling time (DT) following radical prostatectomy or radiation therapy was evaluated as a surrogate end point for prostate cancer specific mortality (PCSM). MATERIALS AND METHODS: Baseline, tr ...
Full textLink to itemCite
Journal ArticleInt J Oncol · October 2004
Understanding of molecular genetic mechanisms underlying prostate carcinogenesis would be greatly advanced by in vitro models of prostate tumors representing primary tumors. We have successfully established a neoplastic immortalized human prostate epitheli ...
Link to itemCite
Journal ArticleClin Prostate Cancer · September 2004
Shorter androgen receptor gene CAG repeat length has been associated with an increased risk of prostate cancer, an earlier age of onset, and more advanced stage of disease. Studies comparing the distribution of CAG repeat lengths within different populatio ...
Full textLink to itemCite
Journal ArticleProstate Cancer Prostatic Dis · September 2004
Combination hormonal therapy, comprising a luteinising hormone-releasing hormone analogue (LHRHa) with an antiandrogen, is widely used in the treatment of advanced prostate cancer. There is ongoing debate regarding the use of combination hormonal therapy a ...
Full textLink to itemCite
Journal ArticleJ Clin Immunol · July 2004
HER2/neu is a proto-oncogene and a member of the epidermal growth factor receptor family of proteins that is overexpressed in numerous types of human cancer. We are currently conducting clinical trials with the HER2/neu E75 peptide vaccine in breast and pr ...
Full textLink to itemCite
Journal ArticleInternational Congress Series · June 1, 2004
We have developed a number of optimal biopsy protocols for the detection of prostate cancer for both general and specific groups of patients. Age, race and prostate volume were considered in the development and optimal protocols were developed for individu ...
Full textCite
Journal ArticleMed Image Anal · June 2004
A methodology is presented for constructing a statistical atlas of spatial distribution of prostate cancer from a large patient cohort, and it is used for optimizing needle biopsy. An adaptive-focus deformable model is used for the spatial normalization an ...
Full textLink to itemCite
Journal ArticleJ Natl Cancer Inst · April 7, 2004
BACKGROUND: Whether the prostate-specific antigen (PSA) response to salvage hormonal therapy can act as an intermediate end point for prostate cancer-specific mortality (PCSM) remains unclear. Therefore, we evaluated whether PSA response, defined as the ab ...
Full textLink to itemCite
Journal ArticleJ Urol · March 2004
PURPOSE: Hormonal therapy (HT) is the current mainstay of systemic treatment for prostate specific antigen (PSA) only recurrence (PSAR), however, there is virtually no published literature comparing HT to observation in the clinical setting. The goal of th ...
Full textLink to itemCite
Journal ArticleJ Urol · March 2004
PURPOSE: Watchful waiting remains an important treatment option for some patients with localized prostate cancer. We defined the demographic, clinical and outcome features of men selecting watchful waiting as an initial treatment strategy, and determined f ...
Full textLink to itemCite
Journal ArticleMed Care · March 2004
BACKGROUND: Previous studies have found that racial/ethnic minority patients with prostate cancer are more frequently managed with "watchful waiting." Little, however, is known about the medical care received among men managed with watchful waiting. We exa ...
Full textLink to itemCite
Journal ArticleJ Gen Intern Med · February 2004
INTRODUCTION: Several recent studies have noted that African Americans disproportionately receive "watchful waiting" for the initial management of their prostate cancer. To determine whether racial/ethnic differences in the receipt of watchful waiting are ...
Full textLink to itemCite
Journal ArticleJ Clin Oncol · February 1, 2004
PURPOSE: To determine if obesity is associated with higher prostate specific antigen recurrence rates after radical prostatectomy (RP), and to explore racial differences in body mass index (BMI) as a potential explanation for the disparity in outcome betwe ...
Full textLink to itemCite
Journal ArticleJ Clin Oncol · February 1, 2004
PURPOSE: To define methodology to show clinical benefit for patients in the state of a rising prostate-specific antigen (PSA). HYPOTHESIS: A clinical states framework was used to address the hypothesis that definitive phase III trials could not be conducte ...
Full textLink to itemCite
Journal ArticleOncogene · January 15, 2004
PCGEM1 is a novel, highly prostate tissue-specific, androgen-regulated gene. Here, we demonstrate that PCGEM1 expression is significantly higher in prostate cancer (CaP) cells of African-American men than in Caucasian-American men (P=0.0002). Further, incr ...
Full textLink to itemCite
Journal ArticleProstate Cancer Prostatic Dis · 2004
INTRODUCTION AND OBJECTIVES: The efficacy of adjuvant and salvage external beam radiation (AXRT+SXRT) for prostate cancer after radical prostatectomy (RP) has been debated because of the inability to rule out systemic occult metastasis, uncertainty that ra ...
Full textLink to itemCite
Journal ArticleRev Urol · 2004
Each year more patients present with prostate cancer at increasingly younger ages and with earlier stage disease, resulting in the potential for longer survival time, longer-term hormonal therapy, and a heightened risk of developing biochemical recurrence ...
Link to itemCite
Journal ArticleUrology · November 2003
OBJECTIVES: To evaluate the efficacy and tolerability of combined finasteride and low-dose flutamide for prostate-specific antigen (PSA)-only recurrence after definitive therapy and to determine the predictors of recurrence-free survival. METHODS: Seventy- ...
Full textLink to itemCite
Journal ArticleJ Clin Oncol · November 1, 2003
PURPOSE: Watchful waiting (WW) is an acceptable strategy for managing prostate cancer (PC) in older men. Prostate-specific antigen (PSA) testing has resulted in a stage migration, with diagnoses made in younger men. An analysis of the Department of Defense ...
Full textLink to itemCite
Journal ArticleJ Natl Cancer Inst · September 17, 2003
BACKGROUND: The relationship between prostate-specific antigen (PSA)-defined recurrence and prostate cancer-specific mortality remains unclear. Therefore, we evaluated the hypothesis that a short post-treatment PSA doubling time (PSA-DT) after radiation th ...
Full textLink to itemCite
Journal ArticleClin Prostate Cancer · September 2003
Prostate cancer is the most common malignancy in American men, accounting for > 29% of all diagnosed cancers and approximately 13% of all cancer deaths. Nearly 1 of every 6 men will be diagnosed with the disease at some time in their lives. In 2003 alone, ...
Full textLink to itemCite
Journal ArticleEur Urol · September 2003
Our understanding of the screening, prevention and treatment of early prostate cancer is improving. This is a result of new data from clinical trials and the incorporation of efficacy measures based on risk assessment and quality of life (QoL). This review ...
Full textLink to itemCite
Journal ArticleCancer Res · August 1, 2003
PMEPA1 was originally identified as a highly androgen-induced gene by serial analysis of gene expression in androgen-treated LNCaP prostate cancer (CaP) cells. PMEPA1 expression is prostate abundant and restricted to prostatic epithelial cells. PMEPA1-enco ...
Link to itemCite
Journal ArticleClin Cancer Res · July 2003
PURPOSE: Prostate-specific antigen (PSA) test has become a widely used screening test in prostate cancer (CaP). However, low specificity of serum PSA leads to many false-positive and false-negative results and clinical uncertainty. Development of CaP-speci ...
Link to itemCite
Journal ArticleInt J Oncol · June 2003
Research into molecular and genetic mechanisms underlying prostate carcinogenesis would be greatly advanced by in vitro models of prostate tumors representing primary tumors. The generation of immortalized primary prostate cancer cells that will accurately ...
Link to itemCite
Journal ArticleJ Clin Oncol · June 1, 2003
PURPOSE: To determine whether pretreatment risk groups shown to predict time to prostate cancer-specific mortality (PCSM) after treatment at a single institution retained that ability in a multi-institutional setting. PATIENTS AND METHODS: From 1988 to 200 ...
Full textLink to itemCite
Journal ArticleJ Urol · May 2003
PURPOSE: In the last decade numerous groups have shown that low levels of pretreatment serum total testosterone consistently predict more aggressive disease, worse prognosis and worse treatment response in patients with metastatic prostate cancer. Prior st ...
Full textLink to itemCite
Journal ArticleInt J Oncol · April 2003
TFPI-2 (tissue factor pathway inhibitor-2) is a serine protease inhibitor that may suppress tumor cell invasion and metastasis. TFPI-2 expression is often lost in cells derived from tumors of diverse organs. We have examined whether aberrant hypermethylati ...
Link to itemCite
Journal ArticleInt J Radiat Oncol Biol Phys · March 15, 2003
PURPOSE: It has traditionally been a common perception that young age is a negative prognostic factor in prostate cancer (CaP). Furthermore, many urologists believe that younger patients are better suited to surgery rather than radiotherapy (RT) because of ...
Full textLink to itemCite
Journal ArticleUrology · March 2003
OBJECTIVES: To develop probability nomograms to predict pathologic outcome at the time of radical prostatectomy (RP) on the basis of established prognostic factors and prostate biopsy quantitative histology. METHODS: Using information from the database of ...
Full textLink to itemCite
Journal ArticleUrology · March 2003
OBJECTIVES: To define the utility of bone scan and computed tomography (CT) in the evaluation of patients with biochemical recurrence after radical prostatectomy. METHODS: A retrospective analysis of the Center for Prostate Disease Research database was un ...
Full textLink to itemCite
Chapter · January 1, 2003
This chapter explores the changes in the prostate specific antigen (PSA) screening test and the prospects for targeted screening of certain groups of individuals who may be at particular risk of developing prostate cancer. Prostate cancer is the most commo ...
Full textCite
Journal ArticleProstate Cancer Prostatic Dis · 2003
Benign prostatic hyperplasia (BPH) involves proliferation of smooth muscle cells and increased deposition of extracellular matrix (ECM). We recently found that pentosan polysulfate (PPS) has marked effects on growth and ECM of smooth muscle cells derived f ...
Full textLink to itemCite
Journal ArticleUrol Oncol · 2003
Prostate cancer recurrence (after prior local treatment) that is detectable only by a rise in serum prostate specific antigen (PSA) level is a very common problem facing clinicians. Given that the majority of contemporary era men with PSA-only or biochemic ...
Full textLink to itemCite
Journal ArticleProstate Cancer Prostatic Dis · 2003
OBJECTIVES: A wide range of p53 mutations (5-65%), detected by various methods, has been reported in primary prostate cancers (CaP). IHC staining of radical prostatectomy specimens shows marked heterogeneity of focally distributed p53-positive cells. Howev ...
Full textLink to itemCite
Journal ArticleUrol Oncol · 2003
OBJECTIVE: Radical retropubic prostatectomy (RRP) pathology from African American (AA) and White men from 1988 to 1999 was examined to determine if the pre-treatment factors PSA, clinical stage, biopsy grade, age at surgery, and year of surgery (YOS) were ...
Full textLink to itemCite
Journal ArticleEur Urol · January 2003
Prostate-specific antigen (PSA) progression following radical treatments of clinically localized prostate cancer is a common problem facing both the patient and the urologist. Not all patients with relapsing disease have an equal risk of death due to prost ...
Full textLink to itemCite
Journal ArticleOncol Rep · 2003
Several investigators have reported the correlation of p53 and bcl-2 immunoreactivity with post operative prostate specific antigen (PSA) recurrence. Focal and or clustered expression is typical for these biomarkers. The purpose of this study was to compar ...
Link to itemCite
Journal ArticleUrol Oncol · 2003
Radical Prostatectomy (RP) has been traditionally associated with significant operative blood loss and high risk of transfusion. However, over the last few years, centers of excellence have reported less bleeding and transfusion. To verify and document cha ...
Full textLink to itemCite
Journal ArticleOncogene · December 12, 2002
Evaluations of androgen regulated gene (ARG) repertoire provide new insights into the androgen receptor (AR) mediated signaling at the transcriptional level. Definition of ARGs having critical functions in the biology of normal and malignant prostate shoul ...
Full textLink to itemCite
Journal ArticleCancer Res · December 1, 2002
Expression of HEPSIN, a type II transmembrane serine protease in prostate cancer (CaP), has been highlighted by several studies analyzing CaP-specific gene expression alterations by cDNA microarray. Evaluations of the biological functions of HEPSIN in CaP ...
Link to itemCite
Journal ArticleSemin Urol Oncol · November 2002
About 5% of all patients with unilateral testis cancer harbor testicular intraepithelial neoplasia (TIN) in their contralateral testicle, which will progress into an invasive germ-cell tumor over time. Accurate diagnosis of TIN by a random surgical testis ...
Full textLink to itemCite
Journal ArticleUrology · November 2002
OBJECTIVES: To determine how the implementation of prostate-specific antigen (PSA) testing has affected disease-specific survival and other characteristics of prostate cancer. METHODS: Data were collected on all patients with prostate cancer diagnosed betw ...
Full textLink to itemCite
Journal ArticleJ Urol · November 2002
PURPOSE: Black men and men with a family history of prostate cancer are at higher risk for this disease and may have an earlier age of onset. Consequently, screening at a younger age has been recommended for high risk men, however, there are limited data o ...
Full textLink to itemCite
Journal ArticleRadiology · November 2002
PURPOSE: To report on the first collaboration of the Department of Defense Center for Prostate Disease Research concerned with the relationship between African American race and biochemical disease-free outcomes after definitive radiation therapy. MATERIAL ...
Full textLink to itemCite
Journal ArticleInt J Oncol · October 2002
Curcumin, traditionally used as a seasoning spice in Indian cuisine, has been reported to decrease the proliferation potential of prostate cancer cells, by a mechanism that is not fully understood. In the current study, we have evaluated the effects of cur ...
Link to itemCite
Journal ArticleMol Med · October 2002
BACKGROUND: Deletion of chromosome 16q is frequently associated with diverse tumors. Numerous studies strongly suggest the presence of one or more tumor suppressor genes on chromosome 16q22 to 16qter including the widely studied cadherin gene family. Howev ...
Link to itemCite
Journal ArticleOncology (Williston Park) · September 2002
Despite the impact of prostate-specific antigen (PSA) testing on the detection and management of prostate cancer, controversy about its usefulness as a marker of disease activity continues. This review, based on a recent roundtable discussion, examines whe ...
Link to itemCite
Journal ArticleSurgery · August 2002
BACKGROUND: Because of public awareness and screening, the incidence of clinically localized prostate cancer has increased dramatically in the last 15 years. The Department of Defense Center for Prostate Disease Research (CPDR) was established by the US Co ...
Full textLink to itemCite
Journal ArticleOncology (Williston Park) · August 2002
Despite the impact of prostate-specific antigen (PSA) testing on the detection and management of prostate cancer, controversy about its usefulness as a marker of disease activity continues. This review, based on a recent roundtable discussion, examines whe ...
Link to itemCite
Journal ArticleClin Prostate Cancer · June 2002
Radical prostatectomy as a primary treatment for clinically localized prostate cancer has increased dramatically over the past decade due to prostate-specific antigen (PSA) screening and the awareness of the increased incidence of localized disease. Despit ...
Full textLink to itemCite
Journal ArticleCurr Urol Rep · June 2002
The introduction of prostate-specific antigen screening has resulted in stage migration and an increased incidence of localized prostate cancer. In this era of increasing nonpalpable disease, it has become necessary to systematically sample the entire pros ...
Full textLink to itemCite
Journal ArticleClin Cancer Res · May 2002
PURPOSE: Expression of tumor suppressor gene, MASPIN, is associated with inhibition of tumor cell invasion and metastasis. Loss of or decreased expression of Maspin is found frequently in breast and prostate cancer cells. The objective of this study is to ...
Link to itemCite
Journal ArticleInt J Oncol · March 2002
Cadmium is a ubiquitous environmental human carcinogen. Epidemiological and animal studies have suggested its carcinogenic potential on the prostate. In the present study, non-tumorigenic human prostate epithelial cells (pRNS-1-1) immortalized by simian pa ...
Link to itemCite
Journal ArticleProstate Cancer Prostatic Dis · 2002
The use of prostate specific antigen (PSA) in the 1990s has brought on a stage migration of prostate cancer. Despite that, many men have still presented with metastatic prostate cancer in the past decade. The use of primary hormone therapy in the PSA era a ...
Full textLink to itemCite
Journal ArticleAnticancer Res · 2002
p63 expression was evaluated in a tissue microarray of prostate tissues including benign glands, prostatic intraepithelial neoplasia and prostatic carcinoma. Immunostaining with anti-p63 antibody was restricted to basal cell nuclei. Detectable p63 was foun ...
Link to itemCite
Journal ArticleProstate Cancer Prostatic Dis · 2002
Physicians and patients have variable and individual levels of comfort regarding when to begin salvage therapy for rising prostate specific antigen (PSA) after definitive treatment of prostate cancer. The decision to start salvage therapy is a multifactori ...
Full textLink to itemCite
Journal ArticleUrol Oncol · 2002
OBJECTIVE: To assess the efficacy of radical prostatectomy (RP) in men presenting with markedly elevated prostate-specific antigen (PSA) levels, the records of 17 patients presenting with serum PSA values > or = 40 ng/mL, who underwent RP at Walter Reed Ar ...
Full textLink to itemCite
Journal ArticleProstate Cancer Prostatic Dis · 2002
The objectives of this work were to evaluate the efficacy of controlled close step-sectioned and whole-mounted radical prostatectomy specimen processing in prediction of clinical outcome as compared to the traditional processing techniques. Two-hundred and ...
Full textLink to itemCite
Journal ArticleProstate Cancer Prostatic Dis · 2002
The objective of this work was to investigate the distribution of prostate cancer using three-dimensional (3-D) computer simulation. Two hundred and eighty-one 3-D computer prostate models were constructed from radical prostatectomy specimens. An algorithm ...
Full textLink to itemCite
Journal ArticleProstate Cancer Prostatic Dis · 2002
The costs of radical prostatectomy and radiation therapy for localized carcinoma of the prostate are well known, the costs of terminal care for men with metastatic disease less so. We sought to determine the costs of terminal care incurred with prostate ca ...
Full textLink to itemCite
Journal ArticleInt J Cancer · December 20, 2001
The purpose of this investigation was to examine changes in pretreatment prostate-specific antigen (PSA), stage, and grade over the past decade as a function of race and geographic region. A multiinstitutional database representing 6,790 patients (1,417 Af ...
Full textLink to itemCite
Journal ArticleUrol Nurs · December 2001
Viadur (leuprolide acetate implant), providing a sustained release of drug over a 12-month duration, decreases serum testosterone in advanced prostate cancer patients, providing long-term, palliative medical hormonal therapy. Clinical experience suggests V ...
Link to itemCite
Journal ArticleOncogene · November 29, 2001
Research into molecular and genetic mechanisms underlying prostate carcinogenesis would be greatly advanced by in vitro models of prostate tumors representing primary tumors. We have successfully established an immortalized human prostate epithelial (HPE) ...
Full textLink to itemCite
Journal ArticleCancer · November 15, 2001
BACKGROUND: The objective was to compare the changes in pathologic and clinical data over time for African-American (AA) and white men with prostate carcinoma undergoing radical prostatectomy in an attempt to determine the early impact of prostate specific ...
Full textLink to itemCite
Journal ArticleUrology · November 2001
OBJECTIVES: To assess serum creatinine as a putative marker for staging/prognosis in localized prostate cancer. Although clinical stage, tumor grade, serum prostate-specific antigen (PSA), and tumor volume assessment by biopsy positivity are established pr ...
Full textLink to itemCite
Journal ArticleUrology · November 2001
OBJECTIVES: To determine whether obesity is associated with more advanced prostate cancer (PCa) in radical prostatectomy patients and to explore the ethnic variability in body mass index (BMI) as a potential explanation for racial differences in PCa risk. ...
Full textLink to itemCite
Journal ArticleJ Urol · October 2001
PURPOSE: It has been shown that black men with clinically localized prostate adenocarcinoma treated with radical prostatectomy have poorer disease-free and disease specific survival than white men with similar tumors. These findings suggest that a potentia ...
Link to itemCite
Journal ArticleJ Urol · October 2001
PURPOSE: Biostatistical models to predict stage or outcome in patients with clinically localized prostate cancer with pretreatment prostate specific antigen (PSA), Gleason sum on biopsy or prostatectomy specimen, clinical or pathological stage and other va ...
Link to itemCite
Journal ArticleProstate Journal · September 27, 2001
Objectives: While controversial, the use of prostate specific antigen (PSA) testing is common and may reduce the morbidity and mortality associated with prostate cancer. The use of age-specific reference ranges (ASRRs) has been suggested to increase the se ...
Full textCite
Journal ArticleUrologic Oncology · September 3, 2001
The Center for Prostate Disease Research (CPDR) database was developed to standardize the clinical procedures for patients with carcinoma of the prostate (CaP), and support retrospective and prospective studies on CaP within the military health care system ...
Full textCite
Journal ArticleUrol Clin North Am · August 2001
For the typical patient who has newly diagnosed prostate cancer, clinically organ-confined disease of moderate grade, and a PSA less than 10 ng/mL, the current role of imaging studies and molecular biomarkers is limited. Bone scans are not necessary for ne ...
Full textLink to itemCite
Journal ArticleInt J Cancer · June 20, 2001
The American Joint Committee on Cancer (AJCC) staging system for prostate cancer adopted in 1992 is based on tumor-node-metastasis (TNM) designations. It has been widely accepted for use in local and advanced disease. The purpose of this study was to asses ...
Full textLink to itemCite
Journal ArticleInt J Cancer · May 1, 2001
Quantitative expression profile of androgen-regulated genes (ARGs) was evaluated in the hormone-responsive prostate cancer cell line LNCaP by serial analysis of gene expression (SAGE). A total of 83,489 SAGE tags representing 23,448 known genes or expresse ...
Full textLink to itemCite
Journal ArticleUrology · April 2001
Prostate-specific antigen (PSA) testing could be used to identify men who are at higher future risk of developing clinical prostate cancer or to diagnose prostate cancer earlier in high-risk groups, such as black men or those with a family history of the d ...
Full textLink to itemCite
Journal ArticleJ Urol · February 2001
PURPOSE: Erectile dysfunction is a common side effect in men treated for prostate cancer. Previously published studies document the incidence of erectile dysfunction in men treated for prostate cancer to be between 20% and 88%. To our knowledge a prospecti ...
Full textLink to itemCite
Chapter · January 1, 2001
An artificial neural network (ANN) is a complex computer system that is designed to replicate human decision making by modelling the human neuron [1-3]. The human brain is made of neurons and millions of multiple synapses, and it is believed that with lear ...
Cite
Journal ArticleBJU Int · January 2001
OBJECTIVE: To review and compare the outcome of patients undergoing radical retropubic prostatectomy (RRP) or radical perineal prostatectomy (RPP) for clinically localized prostate cancer. PATIENTS AND METHODS: From 1988 to 1997, 1382 men who were treated ...
Full textLink to itemCite
Chapter · 2001
Laser-capture microdissection is a recently discovered state-of-the-art method to obtain cells for genetic analysis. It is a one-step procedure that allows capture of selected cells under direct microscopic visualization. ...
Full textLink to itemCite
OtherProceedings of SPIE - The International Society for Optical Engineering · January 1, 2001
Conventional B-mode ultrasound is the standard means of imaging the prostate for guiding prostate biopsies and planning radiotherapy (i.e., brachytherapy and external-beam radiation) of prostate cancer (CaP). Yet B-mode images essentially do not allow visu ...
Full textCite
Journal ArticleComput Aided Surg · 2001
OBJECTIVES: Systematic needle core biopsy is commonly used for the diagnosis of prostate cancer by urologists worldwide. As accurate and early diagnosis will result in more and better options for treatment, it is critical that the best possible protocols f ...
Full textLink to itemCite
OtherProceedings of SPIE - The International Society for Optical Engineering · January 1, 2001
What is the maximal possibility that a physician can detect a prostate cancer, given it is there? This research explores this issue from a statistical point of view and evaluates the theoretical results experimentally. We have collected 300 prostate specim ...
Full textCite
Journal ArticleUrology · December 20, 2000
OBJECTIVES: To analyze the relationships among socioeconomic status (SES), race, and the clinical parameters of patients undergoing radical prostatectomy (RP) in an equal access health care system. METHODS: The Department of Defense Center for Prostate Dis ...
Full textLink to itemCite
Journal ArticleProstate Cancer Prostatic Dis · December 2000
African-American men and black men throughout the world have a higher rate of prostate cancer than other ethnic groups. They also are most likely to present at a younger age with more advanced disease and have historically had a poorer prognosis. Whether t ...
Full textLink to itemCite
Journal ArticleJ Urol · December 2000
PURPOSE: Prostate cancer in men age 50 years or younger traditionally has accounted for approximately 1% of those diagnosed with prostate cancer. Prior studies of prostate cancer in men of this age led many clinicians to believe that they have a less favor ...
Full textLink to itemCite
Journal ArticleCancer Res · December 1, 2000
PSGR, a new prostate tissue-specific gene with homology to the G protein-coupled odorant receptor gene family, has been identified. Here we report the characteristics of the predicted protein sequence of PSGR and its prostate tissue specificity and express ...
Link to itemCite
Journal ArticleUrology · November 1, 2000
OBJECTIVES: To determine the prostate-specific antigen (PSA) levels and PSA change over time in young white and black men 20 to 45 years old. METHODS: The Department of Defense Serum Repository, a serum bank that stores all residual serum from the military ...
Full textLink to itemCite
Journal ArticleProstate Cancer Prostatic Dis · November 2000
Serum albumin level has been implicated as a prognostic factor in various cancers, however it has not been studied in early stage prostate cancer. We examine the clinical prognostic value of the readily available pretreatment albumin level as a marker for ...
Full textLink to itemCite
Journal ArticleProc Natl Acad Sci U S A · October 24, 2000
A prostate-specific gene, PCGEM1, was identified by differential display analysis of paired normal and prostate cancer tissues. Multiple tissue Northern blot analysis revealed that PCGEM1 was expressed exclusively in human prostate tissue. Analysis of PCGE ...
Full textLink to itemCite
Journal ArticleInt J Cancer · October 15, 2000
Transcriptional activation of the p53 target genes plays a critical role in the cellular response to DNA damage, hypoxia, cellular stress and other signals regulating the cell cycle and apoptosis. The discovery of new p53 target genes continues to reveal n ...
Link to itemCite
Journal ArticleEur Urol · October 2000
INTRODUCTION AND OBJECTIVES: The linked p16(INK4)/MTS1 and p15(INK4B)/MTS2 genes on chromosome 9p21 encode proteins that inhibit the cyclinD dependent kinases CDK4/6. Biallelic homozygous deletions involving this locus have been identified in a wide range ...
Full textLink to itemCite
Journal ArticleTech Urol · September 2000
A 71-year-old man presented with acute urinary retention due to benign prostatic hyperplasia and was found to have computed tomography-documented mechanical obstruction of the inferior vena cava (IVC) due to massive hydronephrosis. Obstruction of IVC flow ...
Link to itemCite
Journal ArticleSemin Urol Oncol · August 2000
Carcinoma of the prostate is the most common form of cancer in males in the United States, second only to skin cancer. Recently, there has been increased public awareness of cancer-related diseases and specifically prostate cancer. As a result, more indivi ...
Link to itemCite
Journal ArticleProstate Cancer Prostatic Dis · July 2000
Urologists routinely use the systematic sextant needle biopsy technique to detect prostate cancer. However, recent evidence suggests that this technique has a significant sampling error and data based upon whole-mounted step-sectioned radical prostatectomy ...
Full textLink to itemCite
Journal ArticleGenomics · June 15, 2000
Biologic effects of androgen on target cells are mediated in part by transcriptional regulation of androgen-regulated genes (ARGs) by androgen receptor. Using serial analysis of gene expression (SAGE), we have identified a comprehensive repertoire of ARGs ...
Full textLink to itemCite
Journal ArticleJ Urol · June 2000
PURPOSE: Introduction of the prostate specific antigen (PSA) serum marker for prostate cancer and the subsequent PSA era from 1988 to the present have dramatically altered the diagnosis of the disease. The early to mid 1990s diagnosis boom resulted in a hu ...
Link to itemCite
Journal ArticleCurr Urol Rep · May 2000
African American men are known to have a higher risk of developing prostate cancer. Historically, African American men have presented at a higher stage and had a worse outcome from the disease than non-African American men. There is an ongoing debate wheth ...
Full textLink to itemCite
Journal ArticleJ Biol Chem · March 3, 2000
Maspin has been shown to inhibit tumor cell invasion and metastasis in breast tumor cells. Maspin expression was detected in normal breast and prostate epithelial cells, whereas tumor cells exhibited reduced or no expression. However, the regulatory mechan ...
Full textLink to itemCite
Journal ArticleJ Urol · March 2000
PURPOSE: We determined the incidence of patient self-reported post-prostatectomy incontinence, impotence, bladder neck contracture and/or urethral stricture, sexual function satisfaction, quality of life and willingness to undergo treatment again in a larg ...
Link to itemCite
Journal ArticleJ Urol · March 2000
PURPOSE: NKX3.1, a member of the family of homeobox genes, exhibits prostate tissue specific expression and appears to play a role in mouse prostate development. Rapid induction of NKX3.1 gene expression in response to androgens has also been described. On ...
Link to itemCite
Journal ArticleEur Urol · February 2000
Aim of this review article was to critically analyze the recently described cytogenetic and molecular markers for testicular germ cell tumors with regard to their clinical utility. The isochromosme i(12p) represents the most common and characteristic cytog ...
Full textLink to itemCite
ConferenceLecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics) · January 1, 2000
Prostate cancer is the leading cause of death for American men. The gold standard for diagnosis of prostate cancer is transrectal ultrasound-guided needle core biopsy. Unfortunately, no imaging modality, including ultrasound, can effectively differentiate ...
Full textCite
Journal ArticleJ Urol · January 2000
PURPOSE: Although black men with and without prostatic carcinoma in general have higher levels of prostate specific antigen (PSA) than other racial groups, the cause is unknown. Previous studies have shown that black men produce greater PSA per cc of benig ...
Link to itemCite
Journal ArticleStud Health Technol Inform · 2000
Transrectal Ultrasonography (TRUS) based systematic needle biopsy of the prostate has been widely used clinically in the diagnosis of prostate carcinoma. Current protocols for prostate biopsy, such as the Sextant Protocol, however, have been proven to be i ...
Link to itemCite
Journal ArticleStud Health Technol Inform · 2000
OBJECTIVES: Urologists routinely use the systematic sextant needle biopsy technique to detect prostate cancer. However, recent evidence suggests that this technique has a significant sampling error. Recent data based upon whole-mounted step-sectioned radic ...
Link to itemCite
Journal ArticleMol Urol · 2000
Recurrence after local prostate cancer treatment detectable only by a rise in serum prostate specific antigen (PSA) is a very common problem facing clinicians. Given that the majority of these men are relatively young and otherwise healthy, treatment of PS ...
Link to itemCite
Journal ArticleMol Urol · 2000
The Canadian Urologic Oncology Group has carried out three studies of neoadjuvant hormonal therapy (NHT) in prostate cancer. The first, a study of 3 months of cyproterone acetate (CPA) 100 mg TID in patients undergoing external-beam radiation therapy, show ...
Link to itemCite
Journal ArticleMol Urol · 2000
BACKGROUND: Androgen ablation may improve the efficacy of radiation therapy. PATIENTS AND METHODS: A total of 296 patients who had either (125)I (206; 70%) or (103)Pd (90; 30%) transperineal prostate brachytherapy (no external-beam radiation) had routine t ...
Link to itemCite
Journal ArticleMol Urol · 2000
Since the first suggested use of nuclear magnetic resonance (NMR) for detecting cancer, followed by the demonstration of the feasibility of imaging based on the NMR signal in 1973, magnetic resonance imaging (MRI) has become the modality of choice for a va ...
Link to itemCite
Journal ArticleMol Urol · 2000
Over the past decade, the sextant biopsy technique has emerged as the standard of care in the detection of prostate cancer. This technique is easy to learn and well tolerated by patients and has a major complication rate of <1%. However, limitations in can ...
Link to itemCite
Journal ArticleMol Urol · 2000
BACKGROUND AND PURPOSE: In order to evaluate the effect of short-term androgen blockade on biochemical control rates for high-risk patients receiving a combination regimen of external-beam radiation therapy and low-dose-rate permanent seed implant brachyth ...
Link to itemCite
OtherProceedings of SPIE - The International Society for Optical Engineering · January 1, 2000
Our group has recently obtained data based upon whole-mounted step-sectioned radical prostatectomy specimens using a 3-D computer assisted prostate biopsy simulator that suggests an increased detection rate is possible using laterally placed biopsies. A ne ...
Cite
OtherProceedings of SPIE - The International Society for Optical Engineering · January 1, 2000
In order to develop optimized prostate needle biopsy protocols, we have investigated spatial distribution of prostate tumors using 3D prostate models developed from prostate specimens with localized cancer. An accurate zone-based algorithm has been propose ...
Cite
Journal ArticleJ Urol · December 1999
PURPOSE: Immunohistochemical staining of radical prostatectomy specimens for p53 and bcl-2 proteins has been shown to correlate with prostate specific antigen (PSA) recurrence in a series of patients at our institution. We analyzed the relationship between ...
Full textLink to itemCite
Journal ArticleJ Urol · August 1999
PURPOSE: Black men with and without prostate cancer in general have higher prostate specific antigen (PSA) before screening and treatment than other racial groups. A preliminary study suggested that higher PSA levels may be primarily due to greater tumor b ...
Link to itemCite
Journal ArticleOncology (Williston Park) · July 1999
Patients whose only sign of recurrence after local therapy for prostate cancer is a rising prostate-specific antigen level (PSA-only recurrence) have become more common. We have developed two models to predict PSA-only recurrence after radical prostatectom ...
Link to itemCite
Journal ArticleInt J Cancer · June 21, 1999
Molecular genetic analyses of human prostate cancer (CaP) has revealed frequent loss of specific chromosome regions suggesting the presence of putative tumor suppressor gene(s) (TSG) on these chromosome loci whose inactivation may play a role in prostate t ...
Full textLink to itemCite
Journal ArticleUrol Nurs · June 1999
Prostate cancer is the most common tumor and second most common cause of cancer death in American men. Advanced prostate cancer patients commonly have painful skeletal bony metastases. Although hormonal therapy is very effective initially, hormone-refracto ...
Link to itemCite
Journal ArticleUrology · May 1999
OBJECTIVES: Urologists routinely use the systematic sextant needle biopsy technique to detect prostate cancer. However, recent evidence suggests that this technique has a significant sampling error. We developed a novel three-dimensional (3D) computer-assi ...
Full textLink to itemCite
Journal ArticleUrology · April 1999
OBJECTIVES: The reverse transcriptase-polymerase chain reaction (RT-PCR)-prostate-specific antigen (PSA) assay to detect presumed occult micrometastatic prostate cancer has been controversial, and this molecular staging has been thought to be clinically us ...
Full textLink to itemCite
Journal ArticleJ Urol · April 1999
PURPOSE: The reverse transcriptase polymerase chain reaction (RT-PCR) assay for prostate specific antigen (PSA) expressing cells in the blood circulation has been under intense investigation since 1992. Although it has been suggested that this technology c ...
Link to itemCite
Journal ArticleUrology · January 1999
OBJECTIVES: To assess the ability of pretreatment and post-treatment prostate-specific antigen (PSA) measurements, clinical tumor stage, tumor grade, Gleason sum, race, age, and radiation dose to predict the recurrence of prostate cancer following external ...
Full textLink to itemCite
Journal ArticleProstate Cancer Prostatic Dis · January 1999
This session included five presentations in the areas of pathology of precursor lesions and carcinoma of the prostate, the value of determining neovascularity in the diagnosis and staging of prostate cancer, new 'molecular' markers, correlation between pre ...
Full textLink to itemCite
Journal ArticleEur Urol · 1999
Within the past 5 years, research has increasingly addressed molecular alterations in prostate cancer (CaP). Mutations of tumor suppressor gene p53 have been found in a variety of cancers, including urologic neoplasms. Several studies have been conducted o ...
Full textLink to itemCite
OtherProceedings of SPIE - The International Society for Optical Engineering · January 1, 1999
Urologists routinely use the systematic sextant needle biopsy technique to detect prostate cancer. However, recent evidence suggests that this technique has a significant sampling error. We have developed a novel 3-D computer assisted prostate biopsy simul ...
Full textCite
Journal ArticleStudies in Health Technology and Informatics · January 1, 1999
We have developed a prostate needle biopsy visualization system for the evaluation and optimization of biopsy schemes. Three-dimensional (3-D) prostate surface models have been reconstructed from the digitized whole-mount radical prostetactomy specimens wi ...
Full textCite
Journal ArticleProstate Cancer and Prostatic Diseases · 1999
This session included five presentations in the areas of pathology of precursor lesions and carcinoma of the prostate, the value of determining neovascularity in the diagnosis and staging of prostate cancer, new 'molecular' markers, correlation between pre ...
Cite
OtherProceedings of SPIE - The International Society for Optical Engineering · January 1, 1999
A phased multidisciplinary research work was conducted to develop a master model supported image guidance in prostate biopsy, where a three-dimensional (3D) spatial probability maps of the location of high grade cancer will be constructed based on more tha ...
Full textCite
Journal ArticleUrology · December 1998
OBJECTIVES: To determine the age- and race-specific prostate-specific antigen (PSA) distributions in healthy men in central South Carolina and to compare these to data from other studies. METHODS: Two thousand ninety-two black men aged 40 to 69 years and w ...
Full textLink to itemCite
Journal ArticleUrol Nurs · December 1998
Post-prostatectomy incontinence (PPI) is a common problem in the era of increased detection of prostate cancer and use of radical prostatectomy. Whether temporary or permanent, mild or more severe, PPI can be effectively treated and improved by pelvic musc ...
Link to itemCite
Journal ArticleInt J Androl · October 1998
The aim of this study was to evaluate the clinical utility of immunohistochemical staining of human testicular germ cell tumours with the monoclonal antibody 43-9F to distinguish embryonal carcinoma (EC) from other malignant germ cell components in order t ...
Full textLink to itemCite
Journal ArticleMil Med · September 1998
OBJECTIVE: To predict the risk of extracapsular extension and postoperative recurrence before radical prostatectomy (RP) for prostate cancer. METHODS: We performed multivariate Cox regression analysis on preoperative variables in 260 clinically localized p ...
Link to itemCite
Journal ArticleCancer · September 1, 1998
BACKGROUND: The purpose of this study was to develop a reliable model to identify clinical Stage I nonseminomatous germ cell tumors (NSGCTs) associated with low risk or high risk for occult retroperitoneal metastasis, so that the model could be used to cus ...
Link to itemCite
Journal ArticleProstate Cancer Prostatic Dis · September 1998
The purpose of this study was to determine the incidence of patient-self reported post prostatectomy incontinence, impotence, bladder neck contracture or stricture, better, same or worse quality of life and willingness for same treatment again in a large g ...
Full textLink to itemCite
Journal ArticleUrol Clin North Am · August 1998
Potential tumor markers for testis cancer have become numerous with the new molecular techniques available. New protein markers have been evaluated, and histologic factors have shown correlations with stage of disease. Cytogenetic analysis studies have als ...
Full textLink to itemCite
Journal ArticleJ Urol · August 1998
PURPOSE: We assess the neovascularity of clinically localized prostate cancer by immunohistochemistry using the monoclonal antibody CD34 in an attempt to identify associations between angiogenesis and disease progression following radical prostatectomy. MA ...
Link to itemCite
Journal ArticleUrology · June 1998
OBJECTIVES: Prostate cancer (PCa) has a familial predisposition imparting an increased risk of developing the disease in those with a family history. The pathologic characteristics are similar to sporadic cases; however, the disease-free survival rates of ...
Full textLink to itemCite
Journal ArticleGene Ther · May 1998
Infection of Renca cells in vitro with a recombinant adenovirus expressing a marker gene beta-galactosidase resulted in high level of the transgene expression. Renca tumors grown in Balb/C mice were also infectable with this recombinant adenovirus. The tra ...
Full textLink to itemCite
Journal ArticleJ Urol · May 1998
PURPOSE: p16 (MTS 1) and p15 (MTS 2) are negative regulators of cell cycle progression at the G1 cell cycle checkpoint and function as tumor suppressor genes (TSG). Both p15 and p16 are located on chromosome 9p21 and alterations have been demonstrated in a ...
Full textLink to itemCite
Journal ArticleOncology (Williston Park) · April 1998
The traditional definition of "advanced" prostate cancer includes only patients with widespread osteoblastic or soft-tissue metastases (clinical or pathologic stage T any N any M1; or stage D2). Current evidence indicates that this definition should be bro ...
Link to itemCite
Journal ArticleJ Urol · March 1998
PURPOSE: We examine the clinical prognostic value of the currently available simple and inexpensive immunoenzymatic prostatic acid phosphatase (PAP) assay for the staging and prognosis of radical prostatectomy cases. MATERIALS AND METHODS: Between February ...
Link to itemCite
Journal ArticleJ Urol · March 1998
PURPOSE: Biostatistical models predicting the risk of recurrence after radical prostatectomy for clinically localized prostate cancer are necessary. Identifying these high risk patients shortly after surgery, while tumor burden is minimal, makes them candi ...
Link to itemCite
Chapter · February 1998
Artificial neural networks are computer-based statistical models that can be used to imitate biologic neural processes. They have been applied to a variety of problems in medicine, including diagnosis and outcomes predictions. In the area of urologic oncol ...
Link to itemCite
ConferenceLecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics) · January 1, 1998
The diagnosis of localized prostate cancer is carried out by standard core needle biopsies under guidance of transrectal ultrasound imaging of the prostate gland. This paper describes a 3-D model supported virtual environment for prostate cancer diagnosis ...
Full textCite
ConferenceProceedings - Pacific Medical Technology Symposium: Transcending Time, Distance and Structural Barriers, PACMEDTek 1998 · January 1, 1998
The diagnosis of localized prostate cancer is carried out by standard core needle biopsies under guidance of transrectal ultrasound imaging of the prostate gland. This paper describes a 3D model supported virtual environment for prostate cancer diagnosis a ...
Full textCite
ConferenceProceedings - Pacific Medical Technology Symposium: Transcending Time, Distance and Structural Barriers, PACMEDTek 1998 · January 1, 1998
To detect prostate cancer urologists routinely use the systematic sextant needle biopsy technique. This patterned biopsy technique has been adopted with little quantitative or scientific evidence to support its use. Using 136 digitized radical prostatectom ...
Full textCite
Journal ArticleAPMIS · January 1998
The role of p53 in testicular germ cell tumours is still contradictory based on the finding of immunohistochemical overexpression at the protein level, but lack of mutations at the DNA level. In addition, p53 wild-type activity has been demonstrated in cel ...
Full textLink to itemCite
Journal ArticleUrology · January 1998
Perineal needle tract seeding of prostate cancer is an unusual complication of perineal prostate biopsy. We report a case with the longest known interval from biopsy to perineal recurrence--14 years. The prostate-specific antigen did not become detectable ...
Full textLink to itemCite
Journal ArticleAktuelle Urologie · January 1, 1998
Optimal management of patients with clinical stage I non-seminomatous testicular germ cell tumors remains highly controversial, since all available therapeutic options, such as nerve-sparing retroperitoneal lymphadenectomy, primary chemotherapy and surveil ...
Full textCite
Journal ArticleAktuelle Urologie · January 1, 1998
The p16 gene product is a negative cell cycle regulator and has been shown to be inactivated in a number of primary tumors and cell lines. Overexpression of the myc-family genes has been shown to promote cellular transformation. Myc gene transcriptional ac ...
Full textCite
OtherBritish Journal of Urology · December 1, 1997
Introduction and Objectives : Three dimensional studies of whole mount total prostatectory specimens have revealed the presense of benign prostatic tissue as the surgical margins . The study was undertaken to evaluatte the frequqncy and location of benign ...
Cite
OtherBritish Journal of Urology · December 1, 1997
Introduction and Objectives: Ultrasound guided systematic sextant core needle biopsies of the prostate are commonly used for the detection of prostate cancer. The objective of this study is to evaluate the validity of adequate tumor sampling and tumor volu ...
Cite
OtherBritish Journal of Urology · December 1, 1997
Objective: Percentage of embryonal carcinoma (%EC) and vascular invasion are known risk factors to predict pathological stage II disease in clinical stage I NSGCT. Proliferation markers, cell cycle regulators, proteases and cell to cell adhesion molecules ...
Cite
OtherBritish Journal of Urology · December 1, 1997
Background : Overexpression of both the mutant p53 and bcl-2 proteins in advanced prostate cancer (PC) has been impli-cated in hormone refractory disease and poor prognosis. p53 expression has been shown to be an independent prognostic marker for progressi ...
Cite
OtherAm J Manag Care · August 1997
UNLABELLED: This activity is designed for primary care physicians, internists, and general audiences. GOAL: To provide the reader with a basic understanding of the controversy surrounding population-based prostate cancer screening and of the tools needed t ...
Link to itemCite
Journal ArticleJ Urol · August 1997
PURPOSE: Primary archival tumor tissues of 89 patients with clinical stage I nonseminomatous germ cell tumors were analyzed for MIB-1 expression and histological parameters such as percentage embryonal carcinoma and presence of vascular invasion to determi ...
Link to itemCite
Journal ArticleScand J Urol Nephrol · August 1997
Synchronous bilateral testicular germ cell tumours (TGCT) of different origin are very rare; the simultaneous appearance of a TGCT with a contralateral benign non-germ cell tumour represents an even more seldom event. We report on three patients with nonse ...
Full textLink to itemCite
Journal ArticleCancer · July 1, 1997
BACKGROUND: Higher preoperative prostate specific antigen (PSA) levels are associated with higher pathologic stage and grade in patients undergoing radical prostatectomy (RP). In earlier studies, serum prostate specific membrane antigen (PSMA) elevations w ...
Full textLink to itemCite
Journal ArticleProstate · June 15, 1997
BACKGROUND: Clinical and pathological staging of prostate cancer has been, and remains, problematic. Since prostate-specific antigen (PSA)-detected tumors are often discerned during "screening," what are their significance? METHODS: We analyzed 67 consecut ...
Full textLink to itemCite
Journal ArticlePatient Care · May 15, 1997
With the emergence of new, exotic diseases, it's easy to forget that the diagnosis and management of such ordinary but troublesome infections as peptic ulcer disease, prostatitis, and genital herpes have improved dramatically. So has outcome. ...
Cite
Journal ArticleInt J Cancer · May 2, 1997
We have previously described potent growth-inhibitory effect of a recombinant adenovirus expressing wild type p53 (AdWTp53) in metastatic prostate cancer cells via activation of cellular p53 pathways. We have extended these observations to analyze the effe ...
Full textLink to itemCite
Journal ArticleCancer · March 1, 1997
BACKGROUND: Approximately 50-60% of patients treated with radical prostatectomy for clinically localized prostate carcinoma are found to have microscopic disease that is not organ-confined, and a significant portion of these patients will relapse. Multiple ...
Link to itemCite
Journal ArticleProstate · February 15, 1997
BACKGROUND: The p16 gene product is a negative regulator of cell cycle and has been shown to be deleted or mutated in a number of tumor cell lines and primary tumors. The role of p16 in prostate cancer is not defined. Prostate cancer tissues and cell lines ...
Full textLink to itemCite
Journal ArticleJ Urol · January 1997
PURPOSE: While prostatic manipulation and surgery have been shown to increase serum prostate specific antigen (PSA), the influence of ejaculation on serum PSA remains controversial. We examined the effect of ejaculation on serum PSA levels. MATERIALS AND M ...
Link to itemCite
Journal ArticleJ Urol · January 1997
PURPOSE: Pure testicular teratoma is rare in adulthood with an incidence of 5%. Pure teratoma is considered less aggressive and less likely to metastasize than other nonseminomatous germ cell tumors. Therefore, patients with mature teratoma have been consi ...
Link to itemCite
Journal ArticleTech Urol · 1997
We report two cases of intracranial metastatic adenocarcinoma of the prostate that presented with visual disturbance. The two patients had no prior history of prostate cancer and both underwent invasive neurosurgical procedures. Progressive neurological de ...
Link to itemCite
Journal ArticleUrol Oncol · 1997
This paper presents a retrospective comparison of patients undergoing treatment for clinically localized prostate cancer. We reviewed the age, grade, and stage at diagnosis as well as the survival and recurrence rates of 222 patients treated for carcinoma ...
Full textLink to itemCite
Journal ArticleJournal of Psychosocial Oncology · December 1, 1996
Although prostate cancer is prevalent among older men in the United States today, the problems associated with diagnosis, treatment, and rehabilitation have received scant attention in the psychosocial community. Controversy surrounding the efficacy of tre ...
Full textCite
Journal ArticleMil Med · November 1996
Prostate cancer is a significant health care problem in this country. With an aging population of men, increased public awareness, and use of prostate-specific antigen screening programs, this disease will continue to increase in incidence. This paper addr ...
Link to itemCite
Journal ArticleJ Urol · October 1996
PURPOSE: The tumor suppressor gene (TSG) p53 and the proto-oncogene bcl-2 have been shown to be involved in the regulation of cell growth and apoptosis and have been implicated in hormone refractory prostate cancer (PC) and poor prognosis. The goal of this ...
Link to itemCite
Journal ArticleOncology (Williston Park) · September 1996
Whether patients with clinical stage I nonseminomatous testicular germ-cell cancer (NSGCT) should be treated with orchiectomy and retroperitoneal lymph node dissection (RPLND) or orchiectomy and surveillance remains controversial. Proponents of the former ...
Link to itemCite
Journal ArticleJ Urol · September 1996
PURPOSE: We assessed the cellular proliferation of clinically localized prostate cancer by immunohistochemistry using the monoclonal antibody MIB to Ki-67 antigen in an attempt to identify associations between proliferative indexes and disease progression ...
Link to itemCite
Journal ArticleN Engl J Med · August 1, 1996
BACKGROUND: The detection of prostate cancer by screening for prostate-specific antigen (PSA) in serum is improved when age-specific reference ranges are used, but these ranges have been derived from white populations. We determined the distribution of PSA ...
Full textLink to itemCite
Journal ArticleSurgery · August 1996
BACKGROUND: Protein expression in the primary tumor of the tumor suppressor gene p53 and the proto-oncogene bcl-2 have been shown to be prognostic biomarkers of cancer recurrence after radical prostatectomy in patients with clinically localized prostate ca ...
Full textLink to itemCite
Journal ArticleBone Marrow Transplant · July 1996
Veno-occlusive disease continues to be a significant cause of morbidity and early mortality following bone marrow transplantation. This study retrospectively analyzes the incidence and risk factors for severe VOD in 350 patients treated with 4 days of busu ...
Link to itemCite
Journal ArticleJ Urol · May 1996
PURPOSE: We determined if black men with clinically localized adenocarcinoma of the prostate have the same recurrence-free outcome following radical prostatectomy, and whether they have similar preoperative, operative and pathological characteristics as wh ...
Link to itemCite
Journal ArticleJ Urol · March 1996
PURPOSE: We determined if immunohistochemical expression of the epidermal growth factor receptor and cathepsin D in the primary tumor was of prognostic value in clinically localized prostate cancer after radical prostatectomy. MATERIALS AND METHODS: Immuno ...
Link to itemCite
Journal ArticleTech Urol · 1996
Renal milk-of-calcium (MOC) cysts are rare findings, with only approximately 60 cases reported in the literature. The diagnosis depends on the demonstration of the typical "half-moon" configuration on horizontal beam radiography; classical ultrasound findi ...
Link to itemCite
Journal ArticleProstate Suppl · 1996
BACKGROUND: Prostate-specific antigen (PSA) is a most valuable tool for the early detection of prostate cancer; however, it has a high false-positive rate as presently used in prostate cancer screening programs. Patients with persistent PSA elevations, nor ...
Link to itemCite
Journal ArticleUrology · December 1995
OBJECTIVES: A recombinant adenovirus vector (AdWTp53) expressing wild-type p53 was evaluated for its cell growth inhibitory effects on metastatic human prostate cancer cells. METHODS: Human prostate cancer cells LNCaP, DU145, PC3, 1LN, and DUPro-1 were inf ...
Full textLink to itemCite
Journal ArticleClin Cancer Res · November 1995
Immunohistochemical (IHC) staining for p53 protein nuclear expression was evaluated in archival paraffin-embedded radical prostatectomy specimens from 139 patients with clinically localized prostate cancer followed up from 1 to 8 (mean, 4) years. Elevated ...
Link to itemCite
Journal ArticleJAMA · October 25, 1995
OBJECTIVE: To determine if African-American men with newly diagnosed prostate cancer (PC) have higher pretreatment serum prostate-specific antigen (PSA) values after adjustment for clinical stage, age, and tumor grade, and to determine if any difference de ...
Link to itemCite
Journal ArticleJ Urol · August 1995
PURPOSE: We studied the role of p53 tumor suppressor gene alteration in prostate cancer progression by demonstrating a difference in abnormal p53 findings between early and hormone refractory disease. MATERIALS AND METHODS: The study included p53 immunohis ...
Full textLink to itemCite
Journal ArticleJ Urol · August 1995
PURPOSE: To determine if primary testicular germ cell tumors that overexpress p53 tumor suppressor gene protein have p53 gene mutations. MATERIALS AND METHODS: We examined 30 primary testicular tissues from 26 patients representing two groups. Group one co ...
Full textLink to itemCite
Journal ArticleJ Urol · May 1995
A great deal of controversy exists in staging clinical stage I (CSI) nonseminomatous testicular germ cell tumors (NSGCT) because of the difficulty of distinguishing true stage I patients from those with occult retroperitoneal or distant metastases. The goa ...
Link to itemCite
Chapter · April 1995
The concept of maximal androgen deprivation (MAD) has become the accepted therapy for metastatic prostate cancer. MAD is also under investigation as neoadjuvant therapy prior to radical prostatectomy and radiation therapy. Innovative new approaches, such a ...
Link to itemCite
Journal ArticleTech Urol · 1995
Testicular cancer has become a highly curable neoplasm, and research efforts in the 1990s are focusing on ways to improve staging and treatment so as to limit cost and morbidity. Our group has performed a number of recent studies that help to answer a numb ...
Link to itemCite
Journal ArticleUrol Oncol · 1995
Although interracial differences of prostate cancer progression are well recognized, their underlying molecular and cellular mechanisms remain obscure. We compared the histopathologic, immunohistochemical, and molecular characteristics of unselected prosta ...
Full textLink to itemCite
Journal ArticleMod Pathol · December 1994
Differential reactivity for cathepsin D (cath-D) and epidermal growth factor receptor (EGFR) was compared in 102 archival cases of human primary prostatic carcinoma and nine prostate carcinoma metastases by immunohistochemical techniques using commercially ...
Link to itemCite
Journal ArticleJ Urol · October 1994
We analyzed primary tumor tissue from 89 clinical stage I nonseminomatous germ cell testicular tumor patients for proliferating cell nuclear antigen expression and histological features to determine if these elements could distinguish pathological stage I ...
Full textLink to itemCite
Journal ArticleUrology · October 1994
OBJECTIVES: To examine the accuracy rate of abdominal staging using third and fourth generation computed tomography (CT) scanning in clinical Stage I testicular nonseminoma patients. METHODS: Between January 1985 and August 1993, 57 patients presented to o ...
Full textLink to itemCite
Journal ArticleJ Urol · September 1994
Prostate cancer is rare in young adults and when clinically detected it has been invariably locally or distantly advanced, undifferentiated and exhibiting aggressive behavior. To our knowledge no previous report documents clinically detected and localized ...
Full textLink to itemCite
Journal ArticleUrology · August 1994
OBJECTIVE: To determine the efficacy of computed tomography of the chest (CTC) and plain radiograph (CXR) in the initial staging process of testicular germ cell tumors. METHODS: The medical records of 362 patients with testicular germ cell tumor treated at ...
Full textLink to itemCite
Journal ArticleSurgery · August 1994
BACKGROUND: The purpose of the study was to determine whether a difference is noted in the rate of prostate specific antigen (PSA) elevation after radical prostatectomy or radiation therapy for localized prostate cancer. METHODS: PSA doubling times were ca ...
Link to itemCite
Journal ArticleCancer Res · June 1, 1994
Prostatic tissue specimens derived from transurethral resections of patients with metastatic prostate cancer were analyzed for genetic alterations in the hormone-binding domain of the androgen receptor (AR) gene. Direct sequencing of the polymerase chain r ...
Link to itemCite
Journal ArticleCancer · January 15, 1994
BACKGROUND: The rarity of testis tumor in black patients has made the study of a large series difficult. Much of the epidemiologic and clinical information regarding this neoplasm in this population is in dispute, including data on incidence, prognosis, hi ...
Full textLink to itemCite
OtherCancer Res · January 15, 1994
We analyzed 92 clinical stage I nonseminomatous testicular germ cell tumors for primary tumor histological factors that would distinguish true pathological stage I disease (N = 54) from those patients who harbored occult disease and actually were later fou ...
Link to itemCite
Journal ArticleUrology · January 1994
OBJECTIVE: To test the hypothesis that prostate cancer lymph node (LN) micrometastases, undetected by standard histology, might be found using sensitive immunohistologic methods and may correlate to preoperative prostate-specific antigen (PSA) levels. METH ...
Full textLink to itemCite
Journal ArticleUrology · January 1994
We present the first reported case of a perirenal well-differentiated liposarcoma containing extramedullary hematopoiesis associated with an ipsilateral T2N0M0 renal cell carcinoma. This patient, a seventy-one-year-old white male, had no known hematologic ...
Full textLink to itemCite
Chapter · January 1, 1994
Testicular cancer is the most common solid tumor in men from age 20 to 34 years, and the incidence is increasing. Health care providers, therefore, must consider testicular tumors in their differential diagnosis of scrotal pathology. The persistent problem ...
Cite
Chapter · January 1, 1994
Long-term survival of most testicular cancer patients has put a greater emphasis on treatment morbidity and complications. Vascular and bowel complications are the most common acute complications of retroperitoneal lymphadenectomy. Pulmonary, renal, and ot ...
Cite
Chapter · January 1, 1994
The molecular biologic pathogenesis of testicular germ cell tumors in just beginning to be studied. Extra copies of the short-arm and deletions of portions of the long-arm implicate chromosome 12 in the molecular etiology of these tumors. Specific oncogene ...
Cite
OtherUrology · December 1993
Metastatic stromal cell tumors of the testis are largely refractory to chemotherapy. We report a case of a young man with widely metastatic testicular stromal cell tumor who achieved complete clinical remission following chemotherapy with etoposide, ifosfa ...
Full textLink to itemCite
Journal ArticlePostgrad Med · November 1993
Preview Management of benign prostatic hyperplasia (BPH) is no longer the cut-and-dried topic that it once was. In this article, Dr Moul presents an update on new medical therapies for mild and moderate cases of BPH and on surgical interventions (some expe ...
Full textLink to itemCite
Journal ArticleUrology · November 1993
Synchronous bilateral testis tumors of different histologic types are rare. All previous cases have demonstrated germ cell tumors on both sides. The simultaneous appearance of a germ cell tumor and a contralateral non-germ cell tumor has not been reported. ...
Full textLink to itemCite
Journal ArticlePostgrad Med · November 1, 1993
Many newer treatments are now being proposed for benign prostatic hyperplasia (BPH). Although patients with mild symptoms that do not interfere with their lifestyle can be periodically observed for progression, two classes of medication are being used for ...
Link to itemCite
Journal ArticlePostgrad Med · October 1993
Preview Prostatitis is four diseases rather than one, and successful management depends on accurately classifying the condition according to systemic signs and symptoms and the results obtained by examination of expressed prostatic secretions and urine cul ...
Full textLink to itemCite
Journal ArticleUrology · October 1993
A sixty-eight-year-old black man with clinical Stage A1 (T1a) adenocarcinoma of the prostate was found to have a tortuous and redundant left external iliac artery directly overlying the superior aspect of the prostate gland. The location of this blood vess ...
Full textLink to itemCite
Journal ArticlePostgrad Med · October 1993
Both acute and chronic bacterial prostatitis are generally caused by gram-negative organisms. However, acute infections are seen in younger men and cause fever, difficulty in voiding, low back and perineal pain, and other systemic symptoms. Chronic infecti ...
Link to itemCite
Journal ArticleJ Urol · September 1993
The goal of this study was to determine if deoxyribonucleic acid (DNA) flow cytometric and quantitative histological parameters could predict occult metastases in clinical stage I nonseminomatous testicular cancer. Archival paraffin primary tumor tissue wa ...
Full textLink to itemCite
OtherJ Urol · July 1993
We report 3 cases of gangrene of the penis seen at our institution after penile prosthesis implantation. All 3 patients had insulin-dependent diabetes mellitus. Amputation was required in 2 patients. Aggressive debridement in conjunction with hyperbaric ox ...
Full textLink to itemCite
Journal ArticleJ Urol · June 1993
A variety of human tumors have been studied for ras mutations to date. However, little is known about the prevalence and significance of ras gene activation in adrenal neoplasms. Recently, a study of 10 primary human pheochromocytomas found no evidence for ...
Full textLink to itemCite
OtherJ Urol · February 1993
From November 1985 to April 1990, 216 consecutive patients were treated with the vacuum constriction device. Patients were mailed an initial questionnaire (group 1) and a long-term questionnaire (group 2) at a median followup of 3 and 29 months, respective ...
Full textLink to itemCite
Journal ArticleGenes Chromosomes Cancer · September 1992
Preliminary studies of RAS mutational activation in human testicular germ cell neoplasms have yielded conflicting results. Whereas two studies of clinical material revealed a significant incidence of N- and KRAS mutations, two studies of a variety of germ ...
Full textLink to itemCite
Journal ArticleMil Med · August 1992
A young man presented with a 4-month history of progressive, bilateral tender gynecomastia and underwent a bilateral subcutaneous mastectomy without regard for a possible occult testicular tumor. Following the mastectomy, metastatic testicular cancer was d ...
Link to itemCite
Journal ArticleJ Urol · February 1992
We report an 18-month prospective study of 90 patients undergoing penile prosthesis implantation to evaluate a possible cause-and-effect relationship between degree of diabetic control and the risk of infection complicating the operation. Long-term diabeti ...
Full textLink to itemCite
Journal ArticleJ Urol · February 1992
A 20-year-old man was diagnosed with a left mixed germ cell testicular tumor and clinical staging with computerized tomography suggested left para-aortic subhilar retroperitoneal adenopathy. The patient received 4 cycles of cisplatin, vinblastine and bleom ...
Full textLink to itemCite
Journal ArticleInt Urol Nephrol · 1992
The authors describe a rare case of primary scrotal neoplasm. The necessity of a prompt diagnosis is emphasized. ...
Full textLink to itemCite
Journal ArticleProstate · 1992
The RAS gene family includes three functional genes, H-RAS, K-RAS, and N-RAS, which have been most widely studied in human tumors. Point mutations most commonly occurring at codons 12, 13, or 61 of these genes allow the RAS protooncogene to be converted to ...
Full textLink to itemCite
Journal ArticleJ Urol · January 1992
Retroperitoneal fibrosis, proved by surgical exploration and pathology, was discovered in a patient 13 years after 3,000 rad external beam cobalt retroperitoneal radiation therapy for stage I testicular seminoma. Ureteral obstruction resulted in the loss o ...
Full textLink to itemCite
Journal ArticleJ Urol · January 1992
The sudden onset of pain, swelling and ecchymosis of the penis during sexual intercourse is the typical presentation of traumatic rupture of the corpus cavernosum, commonly termed fracture of the penis. We report a case of isolated traumatic rupture of the ...
Full textLink to itemCite
Journal ArticleJ Urol · October 1991
The superior mesenteric artery and celiac axis were inadvertently ligated during left radical nephrectomy for a large upper pole renal carcinoma with massive perihilar and periaortic adenopathy. Computer-generated 3-dimensional illustrations created from t ...
Full textLink to itemCite
Journal ArticleCancer · September 15, 1991
Twenty-two patients seen between 1975 and 1988 were analyzed who had surgical attempts to cure locally advanced prostate cancer by exenterative procedures or salvage surgery for radiation recurrent disease. Twelve patients (Group I) underwent either a salv ...
Full textLink to itemCite
Journal ArticleUrology · August 1991
We believe this is the fifteenth case report of adrenal cortical carcinoma with tumor thrombus to the vena cava, and the fourth reported case of a left-side tumor propagating thrombus to the vena cava. The patient underwent successful resection which requi ...
Full textLink to itemCite
Journal ArticleWorld Journal of Urology · March 1, 1991
The records of all testicular cancer patients evaluated and treated at our medical center during two consecutive 9-year periods were reviewed and analyzed for prognostic factors, particularly the impact of cisplatin-based combination chemotherapy. The data ...
Full textCite
Journal ArticleJ Urol · November 1990
A total of 441 stage T1-2N0M0 and 11 stage T1-2N0M0 cancer patients with an elevated acid phosphatase level only, and 18 stage T1-2N+M0 cancer patients underwent radical prostatectomy. Analysis of the 441 stage T1-2N0M0 cancer patients demonstrated that fa ...
Full textLink to itemCite
Journal ArticleUrology · October 1990
The M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) regimen has been utilized at our two institutions to treat 17 patients with advanced stage transitional cell carcinoma of the bladder. We report 2 cases of carcinomatous meningitis resulting ...
Full textLink to itemCite
Journal ArticleJ Urol · June 1990
A group of 159 patients previously reported as having margins positive for disease after radical prostatectomy with or without adjunctive postoperative radiation was reanalyzed to determine whether the reported benefit did indeed exist. Upon re-examination ...
Full textLink to itemCite
Journal ArticleJ Urol · March 1990
In an effort to determine the impact of a delayed diagnosis in testicular cancer the records of 148 patients with a known interval of delay were reviewed. The over-all mean symptomatic interval of this population was 21.1 weeks and did not change significa ...
Full textLink to itemCite
Journal ArticleWorld Journal of Urology · March 1, 1990
Of 244 patients with testicular cancer who were treated at our medical center between 1970 and 1987, 7 (2.9%) refused all or a portion of their cancer therapy. All refusers died of cancer, and 6 of the 7 deaths were directly attributable to the refusal. Re ...
Full textCite
Journal ArticleProblems in Urology · January 1, 1990
Post-prostatectomy incontinence (PPI) is a significant problem for both patient and physician. The patient probably had normal urinary control preoperatively, and the sudden lack of control following surgery may overwhelm him. The physician may feel he is ...
Cite
Chapter · January 1, 1990
Renal adenoma has traditionally been described as a solid renal mass less than 3 cm in diameter with a low or absent propensity to metastasize. Histologically, some authorities feel it is distinct from while others feel it represents a variant of renal cel ...
Cite
Chapter · January 1, 1990
A more exacting title for this chapter would be ''Renal Cell Carcinoma: Current problems related to diagnosis, etiology, molecular biology, and the management of localized disease.'' As a chapter on ''Renal Cell Carcinoma'' could easily comprise an entire ...
Cite
Chapter · January 1, 1990
Renal oncocytoma is a distinct, pathologically defined neoplasm composed entirely of oncocytic cells. Current controversy includes differentiating a true benign oncocytoma from a granular eosinophilic renal cell carcinoma (RCC). Previously described 'grade ...
Cite
Journal ArticleJ Urol · December 1989
Of 244 patients with testis cancer seen between January 1970 and December 1987 (mean followup 70 months) 88 (36.1%) experienced 1 or more early complications (within 1 year), while 16 (6.6%) had a late (greater than 1 year) complication. Chemotherapy-relat ...
Full textLink to itemCite
Journal ArticleJ Urol · November 1989
A case of prostate cancer in which the parotid gland was the sole site of metastatic disease is presented. Special immunohistochemical stains of the excisional biopsy allowed for rapid, accurate diagnosis and appropriately directed successful therapy. ...
Full textLink to itemCite
Journal ArticleJ Urol · September 1989
Of 402 penile prosthesis implanted at our institution between 1980 and 1987, 20 required explantation due to infection, erosion, pain or tissue necrosis. Of these 20 patients 14 were available for a prospective trial using a negative pressure device in an ...
Full textLink to itemCite
Journal ArticleJ Urol · July 1989
Between 1975 and 1986, 2,107 perineal prostate biopsies were performed at our institution with 502 (23.8 per cent) positive for prostate cancer. Among this group there were 5 cases (1.0 per cent) of perineal seeding. These 5 cases along with a case referre ...
Full textLink to itemCite
Journal ArticleJ Urol · June 1989
We describe the prospective evaluation of 90 patients seen at 2 medical centers who presented with acute urinary retention. All patients had a pre-retention history obtained, as well as careful prostate examination, perineal prostate biopsy and followup tr ...
Full textLink to itemCite
Journal ArticleUrology · May 1989
Flow cytometry was used to measure the DNA content in archived paraffin-embedded human prostatic cancer tissue for 69 patients with known outcomes that presented between 1975 and 1982. Of these, 51 patients had clinically localized lesions and were surgica ...
Full textLink to itemCite
Journal ArticleJ Urol · July 1988
We reviewed our 5-year surgical experience with undescended testes in 295 patients. Surgery had been performed in a standardized fashion to identify accurately testicular position. Before opening the fascia of the external oblique muscle, the superficial i ...
Full textLink to itemCite
Journal ArticleJ Urol · May 1986
A malleable penile prosthesis incorporating a stainless steel core has been designed to provide a more rigid prosthesis while still ensuring concealability. A total of 56 patients in our initial series underwent implantation of this malleable penile prosth ...
Full textLink to itemCite
